Tuesday, April 29, 2014

Alnylam Up to Positive Data - Analyst Blog

Hot Building Product Companies To Watch For 2015

Alnylam Pharmaceuticals, Inc. (ALNY) recently announced positive top-line results from a phase I study on ALN-TTRsc. The news positively impacted Alnylam share price by 15.8%.

ALN-TTRsc is a ribo nucleic acid interference (RNAi) therapeutic targeting the transthyretin (TTR) gene that is being developed for the treatment of TTR-mediated amyloidosis (ATTR).

Results from the study revealed that ALN-TTRsc was successful in reducing serum TTR protein levels to more than 80% in healthy volunteers who were enrolled in the study. The recent study results were at par with the previously reported ALN-TTRsc results in non-human primates.

Results from the phase I study further revealed that ALN-TTRsc was generally safe and well tolerated. The randomized, double-blind, placebo-controlled, single- and multi-dose, dose-escalation study is still ongoing. Alnylam will assess the safety and tolerability of the candidate (single or multiple ascending subcutaneous doses) along with other parameters like assessment of clinical activity of the candidate as measured by serum TTR levels.

Alnylam plans to initiate a phase II study on ALN-TTRsc later this year depending on the successful completion of the phase I study. Positive results from the phase II study will lead to the initiation of a phase III study on the candidate in 2014.

We remind investors that Alnylam also has ALN-TTR02 in its pipeline that is being developed for the treatment of ATTR. Alnylam is currently evaluating the safety and tolerability of the candidate in a phase II study.

We note that Alnylam has a development and commercialization agreement with Sanofi (SNY) for Alnylam's RNAi therapeutics, which include ALN-TTR02 and ALN-TTRsc. The agreement is for the development and commercialization of these candidates in Japan and the broader Asian-Pacific region.! Alnylam intends to develop and commercialize the ALN-TTR program in other countries as well.

We are encouraged by the pipeline progress at Alnylam. The company is expecting several study results on its RNAi therapeutic candidates in the coming quarters. Positive pipeline related news will boost the stock.

Alnylam, a biopharmaceutical company, presently carries a Zacks Rank #1 (Strong Buy). Other biopharmaceutical stocks such as Jazz Pharmaceuticals Public Limited Company (JAZZ) and Santarus, Inc. (SNTS) also look well positioned with both carrying a Zacks Rank #1.


Monday, April 28, 2014

10 Best Transportation Stocks To Own Right Now

There are a lot of reasons why Delta Air Lines (NYSE: DAL  ) has been earning more money than any other airline in the world. For example, recent cost containment initiatives have helped Delta turn its revenue gains directly into profit growth.

Delta Air Lines has become incredibly reliable -- and profitable -- in the last few years. Source: The Motley Fool

However, for any global network carrier today, keeping business travelers coming back is critical to long-term success. One way to ensure that happens is to reliably deliver good service. Delta does just that -- and trounces other major carriers like American Airlines (NASDAQ: AAL  ) , United Continental (NYSE: UAL  ) , and even Southwest Airlines (NYSE: LUV  ) in terms of service quality.

Consistently good operations
Earlier this week, researchers at Wichita State University and Embry-Riddle Aeronautical University published the annual Airline Quality Rating report. The study measures airline quality through four measures that every airline must report to the Department of Transportation: on-time performance, mishandled baggage, involuntary denied boardings, and official customer complaints.

10 Best Transportation Stocks To Own Right Now: Ryanair (RYAAY)

Ryanair Holdings plc (Ryanair Holdings), incorporated in 1996, is a holding company for Ryanair Limited (Ryanair). Ryanair operates a low-cost, scheduled-passenger airline serving short-haul, point-to-point routes between Ireland, the United Kingdom, Continental Europe, and Morocco. As of June 30, 2012, the Company offered approximately over 1,500 scheduled short-haul flights per day serving approximately 160 airports largely throughout Europe with an operating fleet of 294 aircraft flying approximately 1,500 routes. Ryanair sells seats on a one-way basis. The Company also holds a 29.8% interest in Aer Lingus Group plc. As of June 30, 2012, Ryanair�� operating fleet was composed of 294 Boeing 737-800 aircraft, each having 189 seats. Ryanair�� fleet totaled 294 Boeing 737-800s at March 31, 2012. As of June 30, 2012, Ryanair owned and operated four Boeing 737-800 full flight simulators for pilot training. Ryanair provides ancillary services and engages in other activities connected with its core air passenger service, including non-flight scheduled services, Internet-related services, and the in-flight sale of beverages, food, and merchandise. As part of its non-flight scheduled and Internet-related services Ryanair incentivizes ground service providers at airports it serves to levy correct excess baggage charges for any baggage, which exceeds Ryanair�� published baggage allowances. Excess baggage charges are recorded as non-flight scheduled revenue. Ryanair distributes accommodation services and travel insurance through its Website. For hotel services, Ryanair has a contract with Hotelscombined PTY Ltd. (Hotelscombined), which operates a price comparison Website, pursuant to which Hotelscombined handles all aspects of such services marketed through Ryanair�� Website and pays a fee to Ryanair. Ryanair also has contracts with other accommodation providers that enable Ryanair to offer hostel, bed-and-breakfast, guesthouse, villa and apartment accommodation to its customers. In addition Ryanair has a contract with Hertz, pursuant to which Hertz handles all car rental services marketed through Ryanair�� Website or telephone reservation system. Ryanair also sells bus and rail tickets onboard its aircraft and through its Website. Ryanair also sells attractions and activities on its Website. Ryanair sells gift vouchers on its Website, which are also redeemable online. The Company has an contract with Webloyalty International Ltd, which offers Ryanair�� customers who have a United Kingdom, German or French billing address a retail discount and cash-back program. Ryanair has agreements, pursuant to which the Company promotes Ryanair-branded credit cards issued by MBNA, GE Money, Access Prepaid and Banco Santander on its Internet site. The MBNA agreement relates to Irish residents only, the GE Money agreement relates to Swedish and Polish residents only and the Banco Santander agreement relates to United Kingdom residents only. During the fiscal year ended March 31, 2012, Ryanair rolled out handheld Electronic Point of Sale (EPOS) devices across its route network. These EPOS devices replaced manual and paper based systems on board the aircraft. The EPOS device enables cabin crew to sell and record their on-board sales transactions. The EPOS device also issues bus and rail tickets and tickets for tourist attractions. The Company also offers reserved seating in twenty-one extra legroom seats on each aircraft for a fee on certain routes. Ryanair provides its own aircraft and passenger handling and ticketing services at Dublin Airport. Third parties provide these services to Ryanair at other airports it serves. Servisair plc provides Ryanair�� ticketing, passenger and aircraft handling, and ground handling services at airports in Ireland and the United Kingdom(excluding London (Stansted) Airport where these services are provided by Swissport Ltd.), while similar services in continental Europe are provided by the local airport authorities, either directly or through sub-contractors. Advisors' Opinion:
  • [By El Torero]

    Ryanair (RYAAY) just announced record annual profits of €569 million ($736 million). It expects to break that total this financial year, with predicted profits of between €570 million ($737 million) and €600 million ($776 million). The Irish airline had 79 million passengers last year and it plans on expanding that number with an aggressive expansion strategy, including a number of new routes and with legacy airlines in their sights. Importantly, with Europe deep in economic crisis still, increasing numbers of passengers choose to fly low-cost with Ryanair. With a P/E ratio of 18.52 compared to the industry average of 12.43, according to Reuters, the future looks very bright for Ryanair.

  • [By Jon C. Ogg]

    Ryanair Holdings PLC (NASDAQ: RYAAY) was downgraded to Neutral from Buy at UBS.

    Verizon Communications Inc. (NYSE: VZ) was reiterated as Buy and on the Focus List with a $59 price target at Argus, and it was raised to Outperform at RW Baird.

  • [By Jake L'Ecuyer]

    Ryanair Holdings plc (NASDAQ: RYAAY) was also up, gaining 3.41 percent to $48.86 after the company reported FQ3 results.

    Equities Trading DOWN
    Shares of Ford Motor Co (NYSE: F) were down 3.16 percent to $14.49 after the company reported a 7% drop in its US sales in January.

  • [By GURUFOCUS]

    In the world of publicly-owned businesses, we try to invest with the same sort of individuals. In our opinion, Michael O'Leary, Ryanair's Chairman and CEO, is one such example of a talented, driven executive. Michael was born on a farm in Ireland, the second oldest of six siblings. Although his beginnings were not remarkable, Michael figured out how to get the best education he could by attending the best schools he could. After attending a Jesuit boarding school as a young boy, he graduated from Trinity College with an accounting degree; began his career working for KPMG, a large public accounting firm; and, soon afterwards, became a financial advisor to Tony Ryan, Ryanair's founder. In 1986, Michael was hired to work for Ryan and initially advised him to close the airline immediately since it was losing so much money! In 1989, when Ryanair (RYAAY) was on the brink of insolvency, Ryan offered Michael the job of Deputy CEO of the airline and in 1994 as its CEO. Michael accepted, on the condition that if he couldn't make it profitable, he would be allowed to shut it down! He also chose to work for a percentage of profits rather than for a salary from the money losing business.

10 Best Transportation Stocks To Own Right Now: Saia Inc.(SAIA)

Saia, Inc., an asset-based trucking company, provides transportation and supply chain solutions primarily to the retail, chemical, and manufacturing industries in the United States. The company, through it subsidiary, Saia Motor Freight Line, LLC, offers regional and interregional less than truckload (LTL) services, selected national LTL, and time-definite services. It was formerly known as SCS Transportation, Inc. Saia, Inc. was founded in 2000 and is headquartered in Johns Creek, Georgia.

Advisors' Opinion:
  • [By John Udovich]

    Despite what can best be described as a�soft economy, small cap trucking stocks YRC Worldwide, Inc (NASDAQ: YRCW), Arkansas Best Corporation (NASDAQ: ABFS), Frozen Food Express Industries, Inc (NASDAQ: FFEX), Saia Inc (NASDAQ: SAIA) and USA Truck, Inc (NASDAQ: USAK) have been trucking some pretty impressive returns since the start of the year. In fact, these small cap trucking stocks are up anywhere from 72% to 150% or so since the start of the year despite the slow economy. Certainly trucking stocks provide a good indicator of how the economy is doing, but might investors be�jumping the gun by pushing up these trucking stocks?

Best Cheapest Stocks To Invest In Right Now: Navios Maritime Partners LP (NMM)

Navios Maritime Partners L.P. (Navios Partners) is an international owner and operator of dry cargo vessels formed by Navios Holdings. Navios GP L.L.C. (the General Partner), a wholly owned subsidiary of Navios Maritime Holdings Inc. (Navios Holdings) acts as the general partner of Navios Partners and received a 2% general partner interest in Navios Partners. Navios Partners is engaged in the seaborne transportation services of a range of drybulk commodities, including iron ore, coal, grain and fertilizer, chartering its vessels under medium to long-term charters. On May 19, 2011, Navios Partners acquired from Navios Holdings the Navios Orbiter, a 76,602 deadweight Panamax vessel. On May 19, 2011, Navios Partners acquired from Navios Holdings the Navios Luz. In June 2012, the Company purchased the Navios Buena Ventura, a 2010 South-Korean-built Capesize vessel of 179,259 dwt from Navios Maritime Holdings Inc.

The Company is an international owner and operator of drybulk carriers formed by Navios Maritime Holdings Inc., a vertically integrated seaborne shipping company. Its vessels are chartered-out under medium to long-term time charters with an average remaining term of approximately four years to a group of counterparties, consisting of Cosco Bulk Carrier Co. Ltd., Mitsui O.S.K. Lines Ltd., Samsun Logix, STX Panocean, Sanko Steamship Co. Ltd., Daiichi Chuo Kisen Kaisha, Augustea Imprese Maritime, Rio Tinto, Constellation Energy Group and Mansel.

As of December 31, 2011, the Company�� fleet consisted of 11 Panamax vessels, six Capesize vessels and one Ultra-Handymax vessel. Its fleet of dry cargo vessels has an average age of approximately 5.6 years. Panamax vessels are flexible vessels capable of carrying a range of drybulk commodities, including iron ore, coal, grain and fertilizer. All of its vessels operate under medium to long-term time charters of three or more years at inception with counterparties. It also operates vessels in the spot market until the vessels have! been fixed under appropriate medium to long-term charters.

The Company competes with China Ocean Shipping, China Shipping Group, Mitsui O.S.K. Lines, Kawasaki Kisen, Nippon Yusen Kaisha, Cargill, Pacific Basin Shipping, Bocimar, Zodiac Maritime, Louis Dreyfus/Cetragpa, Cobelfret and Torvald Klaveness.

Advisors' Opinion:
  • [By Igor Greenwald]

    Our Aggressive Portfolio already includes one beneficiary of these trends��avios Maritime Partners (NMM), a partnership with 25 dry bulk carriers, and now, five newly-acquired container ships.

  • [By Eric Volkman]

    As far as unitholder payouts are concerned, the seas for Navios Maritime Partners (NYSE: NMM  ) are calm and smooth. The company has declared its latest quarterly distribution, which is to be $0.4425 per unit paid on Aug. 13 to holders of record as of Aug. 8. That amount matches each of Navios' previous four disbursements, the most recent of which was paid in mid-May. Previous to that, the company handed out a quarter-cent less, at $0.44 per share.

  • [By Bryan Murphy]

    If you're reading this, then odds are you already know shipping stocks like Diana Shipping Inc. (NYSE:DSX), Safe Bulkers, Inc. (NYSE:SB), and Navios Maritime Partners L.P. (NYSE:NMM) are all up big-time today, and up nicely for the week, for that matter. SB is up 11% for the day, NMM is up 6% for the week, while DSX is higher by 8% for the session, snapping a surprisingly-long weak streak.

10 Best Transportation Stocks To Own Right Now: Kinder Morgan Inc (KMI)

Kinder Morgan, Inc. (KMI), incorporated on August 23, 2006, owns and manages a diversified portfolio of energy transportation and storage assets. The Company operates in five business segments: Products Pipelines-KPM, Natural Gas Pipelines-KMP, CO2-KMP, Terminals-KMP and Kinder Morgan Canada-KMP. The Company through Kinder Morgan Energy Partners, L.P. (KMP) operates or owns an interest in approximately 37,000 miles of pipelines and approximately 180 terminals. These pipelines transport natural gas, refined petroleum products, crude oil, carbon dioxide and other products, and its terminals store petroleum products and chemicals, and handle such products as ethanol, coal, petroleum coke and steel. The Company is a provider of carbon dioxide (CO2), for enhanced oil recovery projects in North America. On December 15, 2011, KMP acquired a refined petroleum products terminal located on a 14-acre site in Lorton, Virginia from Motiva Enterprises, LLC. On May 25, 2012, KMI acquired El Paso Corporation. In August 2012, Kinder Morgan Energy Partners, L.P. acquired Tennessee Gas Pipeline (TGP) and a 50% interest in El Paso Natural Gas (EPNG) pipeline from KMI.

NGPL PipeCo LLC consists of its 20% interest in NGPL PipeCo LLC, the owner of Natural Gas Pipeline Company of America LLC and certain affiliates (collectively NGPL), an interstate natural gas pipeline and storage system, which it operates. On November 30, 2011, KMP acquired certain natural gas treating assets from SouthTex Treaters, Inc. On July 1, 2011, KMP acquired from Petrohawk Energy Corporation both the remaining 50% ownership interest in KinderHawk Field Services LLC that KMP did not already own and a 25% equity ownership interest in EagleHawk Field Services LLC. As of December 31, 2011, its interests in KMP and its affiliates consisted of the general partner interest, which the Company holds through its ownership of the general partner of KMP and which entitles the Company to receive incentive distributions; 21.7 million of the 238.0 mi! llion outstanding KMP units, representing an approximately 6.4% limited partner interest, and14.1 million of KMP�� 98.5 million outstanding i-units, representing an approximately 4.2% limited partner interest, through its ownership of 14.1 million Kinder Morgan Management, LLC (KMR) . The Company�� subsidiaries include Kinder Morgan Kansas, Inc. (KMK) and Kinder Morgan Energy Partners, L.P. (KMP).

Products Pipelines-KMP

The segment consists of KMP�� refined petroleum products and natural gas liquids pipelines and their associated terminals, Southeast terminals, and its transmix processing facilities. Products Pipelines-KMP, which consists of approximately 8,400 miles of refined petroleum products pipelines that deliver gasoline, diesel fuel, jet fuel and natural gas liquids to various markets; plus approximately 60 associated product terminals and petroleum pipeline transmix processing facilities serving customers across the United States.

KMP�� West Coast Products Pipelines include the SFPP, L.P. operations (often referred to in this report as the Pacific operations), the Calnev pipeline operations, and the West Coast Terminals operations. The assets include interstate common carrier pipelines regulated by the FERC, intrastate pipelines in the state of California regulated by the California Public Utilities Commission, and certain non rate-regulated operations and terminal facilities. The Pacific operations serve six western states with approximately 2,500 miles of refined petroleum products pipelines and related terminal facilities that provide refined products to population centers in the United States, including California; Las Vegas and Reno, Nevada, and the Phoenix-Tucson, Arizona corridor. During the fiscal year ended February 22, 2012 (fiscal 2011), the Pacific operations��mainline pipeline system transported approximately 1,071,400 barrels per day of refined products, with the product mix being approximately 59% gasoline, 24% diesel fuel, and 17! % jet fue! l.

The Calnev pipeline system consists of two parallel 248-mile, 14-inch and eight-inch diameter pipelines that run from KMP�� facilities at Colton, California to Las Vegas, Nevada. The pipeline serves the Mojave Desert through deliveries to a terminal at Barstow, California and two railroad yards. It also serves Nellis Air Force Base, located in Las Vegas, and also includes approximately 55 miles of pipeline serving Edwards Air Force Base in California. During fiscal 2011, the Calnev pipeline system transported approximately 118,800 barrels per day of refined products, with the product mix being approximately 41% gasoline, 33% diesel fuel, and 26% jet fuel.

KMP owns approximately 51% of Plantation Pipe Line Company, the sole owner of the approximately 3,100-mile refined petroleum products Plantation pipeline system serving the southeastern United States. KMP operates the system pursuant to agreements with Plantation and its wholly-owned subsidiary, Plantation Services LLC. The Plantation pipeline system originates in Louisiana and terminates in the Washington, District of Columbia area. It connects to approximately 130 shipper delivery terminals throughout eight states and serves as a common carrier of refined petroleum products to various metropolitan areas, including Birmingham, Alabama; Atlanta, Georgia; Charlotte, North Carolina, and the Washington, District of Columbia area. An affiliate of ExxonMobil Corporation owns the remaining approximately 49% ownership interest, and ExxonMobil has historically been one of the shippers on the Plantation system both in terms of volumes and revenues. In fiscal 2011, Plantation delivered approximately 518,000 barrels per day of refined petroleum products, with the product mix being approximately 67% gasoline, 20% diesel fuel, and 13% jet fuel.

KMP owns 50% of Cypress Interstate Pipeline LLC, the sole owner of the Cypress pipeline system. KMP operates the system pursuant to a long-term agreement. The Cypress pipeline is a! n interst! ate common carrier natural gas liquids pipeline originating at storage facilities in Mont Belvieu, Texas and extending 104 miles east to a connection with Westlake Chemical Corporation, a petrochemical producer in the Lake Charles, Louisiana area. Mont Belvieu, located approximately 20 miles east of Houston, is a hub for natural gas liquids gathering, transportation, fractionation and storage in the United States. The Cypress pipeline system has a capacity of approximately 55,000 barrels per day for natural gas liquids. In fiscal 2011, the system transported approximately 45,000 barrels per day.

KMP�� Southeast terminal operations consist of 27 liquid petroleum products terminals located along the Plantation/Colonial pipeline corridor in the Southeastern United States. The marketing activities of the Southeast terminal operations are focused on the Southeastern United States from Mississippi through Virginia, including Tennessee. The primary function involves the receipt of petroleum products from common carrier pipelines, short-term storage in terminal tankage, and subsequent loading onto tank trucks. Combined, the Southeast terminals have a total storage capacity of approximately 9.1 million barrels. In fiscal 2011, these terminals transferred approximately 353,000 barrels of refined products per day and together handled 9.2 million barrels of ethanol.

KMP�� Transmix operations include the processing of petroleum pipeline transmix, a blend of dissimilar refined petroleum products that have become co-mingled in the pipeline transportation process. During pipeline transportation, different products are transported through the pipelines abutting each other, and generate a volume of different mixed products called transmix. KMP processes and separates pipeline transmix into pipeline-quality gasoline and light distillate products at six separate processing facilities located in Colton, California; Richmond, Virginia; Dorsey Junction, Maryland; Indianola, Pennsylvania; Wood Riv! er, Illin! ois; and Greensboro, North Carolina. Combined, KMP�� transmix facilities processed approximately 10.6 million barrels of transmix in 2011.

Natural Gas Pipelines-KMP

Natural Gas Pipelines-KMP, which consists of approximately 16,200 miles of natural gas transmission pipelines and gathering lines, plus natural gas storage, treating and processing facilities, through which natural gas is gathered, transported, stored, treated, processed and sold. The Natural Gas Pipelines-KMP business segment contains both interstate and intrastate pipelines. Its primary businesses consist of natural gas sales, transportation, storage, gathering, processing and treating. Within this segment, KMP owns approximately 16,200 miles of natural gas pipelines and associated storage and supply lines that are strategically located at the center of the North American pipeline grid. KMP�� transportation network provides access to the gas supply areas in the western United States, Texas and the Midwest, as well as consumer markets.

KMP�� subsidiary, Kinder Morgan Treating, L.P., owns and operates (or leases to producers for operation) treating plants that remove impurities (such as carbon dioxide and hydrogen sulfide) and hydrocarbon liquids from natural gas before it is delivered into gathering systems and transmission pipelines to ensure that it meets pipeline quality specifications. Additionally, its subsidiary KM Treating Production LLC designs, constructs, and sells custom and stock natural gas treating plants. Combined, KMP�� rental fleet of treating assets include approximately 213 natural gas amine-treating plants, approximately 56 hydrocarbon dew point control plants, and more than 140 mechanical refrigeration units that are used to remove impurities and hydrocarbon liquids from natural gas streams prior to entering transmission pipelines.

KinderHawk Field Services LLC gathers and treats natural gas in the Haynesville shale gas formation located in northwest Louisiana.! Its asse! ts consist of more than 450 miles of natural gas gathering pipeline in service, with average throughput of approximately 1.1 billion cubic feet per day of natural gas. Additionally, the system�� natural gas amine treating plants have a capacity of approximately 2,600 gallons per minute. During 2011, KinderHawk executed firm gathering and treating agreements with a third-party producer for the long-term of five sections. KinderHawk also holds additional third-party gas gathering and treating commitments. In total, these contracts provide for the dedication of 36 sections, from four shippers, for 3 to 10 years. EagleHawk Field Services LLC provides natural gas gathering and treating services in the Eagle Ford shale formation in South Texas.

KMP owns a 40% interest in Endeavor Gathering LLC, which provides natural gas gathering service to GMX Resources��exploration and production activities in its Cotton Valley Sands and Haynesville/Bossier Shale horizontal well developments located in East Texas. GMX Resources, Inc. operates and owns the remaining 60% ownership interest in Endeavor Gathering LLC. Endeavor�� gathering system consists of over 100 miles of gathering lines and 25,000 horsepower of compressors that collect and compress natural gas from GMX Resources��operated natural gas production from wells located in its core area. The natural gas gathering system has takeaway capacity of approximately 115 million cubic feet per day. KMP owns a 50% equity interest in Eagle Ford Gathering LLC, which provides natural gas gathering, transportation and processing services to natural gas producers in the Eagle Ford shale gas formation in south Texas.

KMP�� Natural Gas Pipelines��upstream operations consist of its Casper and Douglas, Wyoming natural gas processing operations and its 49% ownership interest in the Red Cedar Gas Gathering Company. KMP owns and operates its Casper and Douglas, Wyoming natural gas processing plants, and combined, these plants have the capacity ! to proces! s up to 185 million cubic feet per day of natural gas depending on raw gas quality. Casper and Douglas are the natural gas processing plants, which provide straddle processing of natural gas flowing into KMP�� Kinder Morgan Interstate Gas Transmission LLC pipeline system. KMP also owns the operations of a carbon dioxide/sulfur treating facility located in the West Frenchie Draw field of the Wind River Basin of Wyoming, and includes this facility as part of its Casper and Douglas operations. The West Frenchie Draw treating facility has a capacity of 50 million cubic feet per day of natural gas.

KMP owns a 49% interest in the Red Cedar Gathering Company (Red Cedar). Red Cedar owns and operates natural gas gathering, compression and treating facilities in the Ignacio Blanco Field in La Plata County, Colorado. The remaining 51% interest in Red Cedar is owned by the Southern Ute Indian Tribe. Red Cedar�� natural gas gathering system consists of approximately 750 miles of gathering pipeline connecting more than 900 producing wells, 104,600 horsepower of compression at 22 field compressor stations and three carbon dioxide treating plants. The capacity and throughput of the Red Cedar gathering system is approximately 600 million cubic feet per day of natural gas.

KMP�� subsidiary, TransColorado Gas Transmission Company LLC (TransColorado), owns a 300-mile interstate natural gas pipeline that extends from approximately 20 miles southwest of Meeker, Colorado to the Blanco Hub near Bloomfield, New Mexico. KMP operates and owns 50% of the 1,679-mile Rockies Express natural gas pipeline system, a natural gas pipelines constructed in North America. The Rockies Express system consists of three pipeline segments: a 327-mile pipeline that extends from the Meeker Hub in northwest Colorado, across southern Wyoming to the Cheyenne Hub in Weld County, Colorado, a 713-mile pipeline from the Cheyenne Hub to an interconnect in Audrain County, Missouri and a 639-mile pipeline from Audrain Count! y, Missou! ri to Clarington, Ohio. KMP�� ownership is through its 50% equity interest in Rockies Express Pipeline LLC, the sole owner of the Rockies Express pipeline system. Sempra Pipelines & Storage, a unit of Sempra Energy, and ConocoPhillips each own 25% of Rockies Express Pipeline LLC.

The Rockies Express pipeline system is powered by 18 compressor stations totaling approximately 427,000 horsepower. The system is capable of transporting two billion cubic feet per day of natural gas from Meeker, Colorado to the Cheyenne Market Hub in northeastern Colorado and 1.8 billion cubic feet per day from the Cheyenne Hub to the Clarington Hub in Monroe County in eastern Ohio. Capacity on the Rockies Express system is contracted under 10 year firm service agreements with producers from the Rocky Mountain supply basin. These agreements provide the pipeline with fixed monthly reservation revenues for the primary term of such contracts through 2019, with the exception of one agreement representing approximately 10% of the pipeline capacity that grants a shipper the one-time option to terminate effective late 2014. With its connections to numerous other pipeline systems along its route, the Rockies Express system has access to almost all of the gas supply basins in Wyoming, Colorado and eastern Utah. Rockies Express is capable of delivering gas to multiple markets along its pipeline system, primarily through interconnects with other interstate pipeline companies and direct connects to local distribution companies.

KMP�� Central interstate natural gas pipeline group, which operates primarily in the Mid-Continent region of the United States, consists of four natural gas pipeline systems: Trailblazer Pipeline, Kinder Morgan Louisiana Pipeline, KMP�� 50% ownership interest in the Midcontinent Express Pipeline and KMP�� 50% ownership interest in the Fayetteville Express Pipeline. KMP�� subsidiary, Trailblazer Pipeline Company LLC (Trailblazer), owns the 436-mile Trailblazer natural gas pipelin! e system.! The Trailblazer pipeline system originates at an interconnection with Wyoming Interstate Company Ltd.�� pipeline system near Rockport, Colorado and runs through southeastern Wyoming to a terminus near Beatrice, Nebraska where it interconnects with NGPL�� and Northern Natural Gas Company�� pipeline systems. NGPL manages, maintains and operates the Trailblazer system for KMP, for which it is reimbursed at cost. Trailblazer offers its customers firm and interruptible transportation, and in 2011, it transported an average of approximately 717 million cubic feet per day of natural gas.

KMP�� subsidiary, Kinder Morgan Louisiana Pipeline LLC owns the Kinder Morgan Louisiana natural gas pipeline system. KMP owns a 50% interest in Midcontinent Express Pipeline LLC, the sole owner of the approximate 500-mile Midcontinent Express natural gas pipeline system. KMP also operates the Midcontinent Express pipeline system. Regency Midcontinent Express LLC owns the remaining 50% ownership interest. The Midcontinent Express pipeline system originates near Bennington, Oklahoma and extends eastward through Texas, Louisiana, and Mississippi, and terminates at an interconnection with the Transco Pipeline near Butler, Alabama. It interconnects with numerous pipeline systems and provides an important infrastructure link in the pipeline system moving natural gas supply from newly developed areas in Oklahoma and Texas into the United States��eastern markets. The pipeline system is comprised of approximately 30-miles of 30-inch diameter pipe, 275-miles of 42-inch diameter pipe and 197-miles of 36-inch diameter pipe. Midcontinent Express also has four compressor stations and one booster station totaling approximately 144,500 horsepower. It has two rate zones: Zone 1 (which has a capacity of 1.8 billion cubic feet per day) beginning at Bennington and extending to an interconnect with Columbia Gulf Transmission near Delhi, in Madison Parish Louisiana and Zone 2 (which has a capacity of 1.2 billion cubic feet ! per day) ! beginning at Delhi and terminating at an interconnection with Transco Pipeline near the town of Butler in Choctaw County, Alabama. Capacity on the Midcontinent Express system is 99% contracted under long-term firm service agreements that expire between 2012 and 2021. The ity of volume is contracted to producers moving supply from the Barnett shale and Oklahoma supply basins.

CO2-KMP

The CO2-KMP business segment consists of Kinder Morgan CO2 Company, L.P. and its consolidated affiliates, (collectively referred to KMCO2). The CO2-KMP business segment produces, transports, and markets carbon dioxide for use in enhanced oil recovery projects as a flooding medium for recovering crude oil from mature oil fields. CO2-KMP, which produces, markets and transports, through approximately 2,000 miles of pipelines, carbon dioxide to oil fields that use carbon dioxide to increase production of oil; owns interests in and/or operates eight oil fields in West Texas; and owns and operates a 450-mile crude oil pipeline system in West Texas

KMCO2 holds ownership interests in oil-producing fields located in the Permian Basin of West Texas, including an approximate 97% working interest in the SACROC unit; an approximate 50% working interest in the Yates unit; an approximate 21% net profits interest in the H.T. Boyd unit; an approximate 65% working interest in the Claytonville unit; an approximate 99% working interest in the Katz Strawn unit, and lesser interests in the Sharon Ridge unit, the Reinecke unit and the MidCross unit.

KMCO2 operates and owns an approximate 65% gross working interest in the Claytonville oil field unit and operates and owns an approximate 99% working interest in the Katz Strawn unit, both located in the Permian Basin area of West Texas. The Claytonville unit is located approximately 30 miles east of the SACROC unit, in Fisher County, Texas. The unit produced approximately 200 gross barrels of oil per day during 2011 (100 net barrels to KMCO2! per day)! . During 2011, the Katz Strawn unit produced approximately 500 barrels of oil per day (400 net barrels to KMCO2 per day). In 2011, the average purchased carbon dioxide injection rate at the Katz Strawn unit was 46 million cubic feet per day.

KMCO2 operates and owns an approximate 22% working interest plus an additional 28% net profits interest in the Snyder gasoline plant. KMCO2 also operates and owns a 51% ownership interest in the Diamond M gas plant and a 100% ownership interest in the North Snyder plant, all of which are located in the Permian Basin of West Texas. The Snyder gasoline plant processes natural gas produced from the SACROC unit and neighboring carbon dioxide projects, specifically the Sharon Ridge and Cogdell units, all of which are located in the Permian Basin area of West Texas. The Diamond M and the North Snyder plants contract with the Snyder plant to process natural gas. Production of natural gas liquids at the Snyder gasoline plant during 2011 averaged approximately 16,600 gross barrels per day (8,300 net barrels to KMCO2 per day excluding the value associated to KMCO2�� 28% net profits interest).

KMCO2 owns approximately 45% of, and operates, the McElmo Dome unit in Colorado, which contains more than 6.6 trillion cubic feet of recoverable carbon dioxide. It also owns approximately 87% of, and operates, the Doe Canyon Deep unit in Colorado, which contains more than 870 billion cubic feet of carbon dioxide. For both units combined, compression capacity exceeds 1.4 billion cubic feet per day of carbon dioxide and during 2011, the two units produced approximately 1.25 billion cubic feet per day of carbon dioxide. KMCO2 also owns approximately 11% of the Bravo Dome unit in New Mexico. The Bravo Dome unit contains more than 800 billion cubic feet of recoverable carbon dioxide and produced approximately 300 million cubic feet of carbon dioxide per day in 2011. As a result of KMP�� 50% ownership interest in Cortez Pipeline Company, it owns a 50% equity inter! est in an! d operates the approximate 500-mile Cortez pipeline. The pipeline carries carbon dioxide from the McElmo Dome and Doe Canyon source fields near Cortez, Colorado to the Denver City, Texas hub. The Cortez pipeline transports over 1.2 billion cubic feet of carbon dioxide per day. The tariffs charged by the Cortez pipeline are not regulated, but are based on a consent decree.

KMCO2 also owns a 13% undivided interest in the 218-mile, Bravo pipeline, which delivers carbon dioxide from the Bravo Dome source field in northeast New Mexico to the Denver City hub and has a capacity of more than 350 million cubic feet per day. Tariffs on the Bravo pipeline are not regulated. Occidental Petroleum (81%) and XTO Energy (6%) hold the remaining ownership interests in the Bravo pipeline. In addition, KMCO2 owns approximately 98% of the Canyon Reef Carriers pipeline and approximately 69% of the Pecos pipeline. The Canyon Reef Carriers pipeline extends 139 miles from McCamey, Texas, to the SACROC unit in the Permian Basin. The pipeline has a capacity of approximately 270 million cubic feet per day and makes deliveries to the SACROC, Sharon Ridge, Cogdell and Reinecke units. The Pecos pipeline is a 25-mile pipeline that runs from McCamey to Iraan, Texas. It has a capacity of approximately 120 million cubic feet per day and makes deliveries to the Yates unit. The tariffs charged on the Canyon Reef Carriers and Pecos pipelines are not regulated.

Terminals-KMP

The Terminals-KMP business segment includes the operations of KMP�� petroleum, chemical and other liquids terminal facilities (other than those included in the Products Pipelines-KMP business segment) and all of its coal, petroleum coke, fertilizer, steel, ores and other dry-bulk material services facilities, including all transload, engineering, conveying and other in-plant services. Combined, the segment is composed of approximately 115 owned or operated liquids and bulk terminal facilities and approximately 35 rail transloadin! g and mat! erials handling facilities. The terminals are located throughout the United States and in portions of Canada.

KMP�� liquids terminals operations primarily store refined petroleum products, petrochemicals, ethanol, industrial chemicals and vegetable oil products in aboveground storage tanks and transfer products to and from pipelines, vessels, tank trucks, tank barges, and tank railcars. Combined, KMP�� approximately 25 liquids terminals facilities possess liquids storage capacity of approximately 60.2 million barrels, and in 2011, these terminals handled approximately 616 million barrels of liquids products, including petroleum products, ethanol and chemicals. KMP�� bulk terminal operations primarily involve dry-bulk material handling services. KMP also provides conveyor manufacturing and installation, engineering and design services, and in-plant services covering material handling, conveying, maintenance and repair, truck-railcar-marine transloading, railcar switching and miscellaneous marine services. KMP owns or operates approximately 90 dry-bulk terminals in the United States and Canada, and combined, its dry-bulk and material transloading facilities handled approximately 100.6 million tons of coal, petroleum coke, fertilizers, steel, ores and other dry-bulk materials in 2011.

Kinder Morgan Canada-KMP

The Kinder Morgan Canada-KMP business segment includes the Trans Mountain pipeline system, KMP�� ownership of a one-third interest in the Express pipeline system, and the 25-mile Jet Fuel pipeline system. The Trans Mountain pipeline system originates at Edmonton, Alberta and transports crude oil and refined petroleum products to destinations in the interior and on the west coast of British Columbia. Trans Mountain�� pipeline is 715 miles in length. KMP also owns a connecting pipeline that delivers crude oil to refineries in the state of Washington. The capacity of the line at Edmonton ranges from 300,000 barrels per day when heavy crude represents 20% ! of the to! tal throughput (which is a historically normal heavy crude percentage), to 400,000 barrels per day with no heavy crude. Trans Mountain is the sole pipeline carrying crude oil and refined petroleum products from Alberta to the west coast.

In 2011, Trans Mountain delivered an average of 274,000 barrels per day. The crude oil and refined petroleum products transported through Trans Mountain�� pipeline system originates in Alberta and British Columbia. The refined and partially refined petroleum products transported to Kamloops, British Columbia and Vancouver originates from oil refineries located in Edmonton. Petroleum products delivered through Trans Mountain�� pipeline system are used in markets in British Columbia, Washington State and elsewhere offshore. Trans Mountain also operates a 5.3 mile spur line from its Sumas Pump Station to the United States.-Canada international border where it connects with KMP�� approximate 63-mile, 16-inch to 20-inch diameter Puget Sound pipeline system. The Puget Sound pipeline system in the state of Washington has a sustainable throughput capacity of approximately 135,000 barrels per day when heavy crude represents approximately 25% of throughput, and it connects to four refineries located in northwestern Washington State. The volumes of crude oil shipped to the state of Washington fluctuate in response to the price levels of Canadian crude oil in relation to crude oil produced in Alaska and other offshore sources.

NGPL PipeCo LLC

The Company owns a 20% interest in NGPL PipeCo LLC and account for its interest as an equity method investment. The Company continues to operate NGPL PipeCo LLC�� assets pursuant to an operations and reimbursement agreement effective through February 15, 2023. NGPL PipeCo LLC owns a interstate gas pipeline and storage system consisting primarily of two interconnected natural gas transmission pipelines terminating in the Chicago, Illinois metropolitan area. NGPL�� Amarillo Line originates in th! e West Te! xas and New Mexico producing areas and is comprised of approximately 4,400 miles of mainline and various small-diameter pipelines. Its other pipeline, the Gulf Coast Line, originates in the Gulf Coast areas of Texas and Louisiana and consists of approximately 4,100 miles of mainline and various small-diameter pipelines. These two main pipelines are connected at points in Texas and Oklahoma by NGPL�� approximately 800-mile Amarillo/Gulf Coast pipeline.

NGPL is a natural gas storage operator with approximately 600 billion cubic feet of total natural gas storage capacity, approximately 278 billion cubic feet of working gas capacity and over 4.3 billion cubic feet per day of peak deliverability from its storage facilities, which are located in supply areas and near the markets it serves. NGPL owns and operates 13 underground storage reservoirs in eight field locations in four states. These storage assets complement its pipeline facilities and allow it to optimize pipeline deliveries and meet peak delivery requirements in its principal markets.

Advisors' Opinion:
  • [By Aimee Duffy]

    Kinder Morgan (NYSE: KMI  ) is the third-largest energy company in the U.S. by enterprise value. But make no mistake, this company is far from a lurching, unwieldy conglomerate. Kinder Morgan and its master limited partnerships, Kinder Morgan Energy Partners (NYSE: KMP  ) and El Paso Pipeline Partners (NYSE: EPB  ) , form a nimble and diverse partnership, able to weather the effect of whatever the energy world throws at it. In this video, Fool.com contributor Aimee Duffy examines the opportunity at Kinder Morgan, and offers up examples of how the partnership is able to mitigate tough times and succeed when others fail.

10 Best Transportation Stocks To Own Right Now: Western Refining Logistics LP (WNRL)

Western Refining Logistics, LP, incorporated on July 17, 2013, owns, operates, develops, and acquires terminals, storage tanks, pipelines, and other logistics assets. As of December 31, 2012, the Company�� assets includes pipeline and gathering assets and terminalling, transportation, and storage assets in the Southwestern portion of the United States, which included approximately 300 miles of pipelines and approximately 7.9 million barrels of active storage capacity, as well as other assets. The Company's assets are integral to the operations of Western�� refineries located in El Paso, Texas, and near Gallup, New Mexico.

As of December 31, 2012, the Company owns and operates two refineries, in El Paso, Texas and Gallup, New Mexico, with a total crude oil throughput capacity of 153,000 barrels per day (bpd). The Company does not take ownership of the hydrocarbons or products (other than certain additives) that it handles or engages in the trading of any commodities.

Advisors' Opinion:
  • [By Robert Rapier]

    Western Refining Logistics (NYSE: WNRL) debuted on Oct. 10. The partnership was formed by Western Refining (NYSE: WNR) to own, operate, develop and acquire terminals, storage tanks, pipelines, and other logistics assets. WNRL’s assets include 300 miles of crude oil pipelines, gathering systems, and 566,000 barrels of crude oil storage located primarily in the Permian Basin. Most of its revenue is expected to be derived from two 10-year, fee-based agreements with Western Refining.

  • [By Aimee Duffy]

    It;s been a very robust year for master limited partnership IPOs to say the least. On Thursday, Western Refining (NYSE: WNR  ) successfully spun off its midstream logistics MLP, Western Refining Logistics (NYSE: WNRL  ) . The partnership became the 14th MLP to make its debut this year.

10 Best Transportation Stocks To Own Right Now: Pembina Pipeline Corp (PBA)

Pembina Pipeline Corporation (Pembina) is a Calgary-based company, engaged in providing transportation and midstream services. It owns and operates: pipelines that transport conventional and synthetic crude oil and natural gas liquids produced in western Canada; oil sands, heavy oil and diluent pipelines; gas gathering and processing facilities; and, an oil and natural gas liquids infrastructure and logistics business. It has facilities located in western Canada and in natural gas liquids markets in eastern Canada and the United States. Pembina also offers a spectrum of midstream and marketing services. Pembina�� Midstream business is organized into two segments: crude oil and NGL. The crude oil segment represents the Company�� midstream operations. The NGL segment includes two operating systems: Redwater West and Empress East. Pembina's Conventional Pipelines business consists of a pipeline network, located 7,850 kilometers, that extends across much of Alberta and British Columbia. Advisors' Opinion:
  • [By Rich Duprey]

    Midstream operator�Pembina Pipeline� (NYSE: PBA  ) �announced yesterday its monthly dividend for May of $0.135 per share,�which is designated an "eligible dividend" for Canadian income tax purposes. For non-resident shareholders, Pembina's dividends are considered "qualified dividends" and are subject to Canadian withholding tax.

  • [By Rich Duprey]

    Midstream operator Pembina Pipeline (NYSE: PBA  ) announced yesterday its monthly dividend for July, of $0.135 per share, which is designated an "eligible dividend" for Canadian income tax purposes. For non-resident shareholders, Pembina's dividends are considered "qualified dividends," subject to Canada's withholding tax.

  • [By Vanin Aegea]

    Two companies that have been around for some time now are Imperial Oil (IMO) and Pembina Pipeline (PBA). Political instability in the Middle East has also given an extra relevance to the reserves found at this region, so let us see what the future holds and what gurus think of them.

10 Best Transportation Stocks To Own Right Now: EQT Midstream Partners LP (EQM)

EQT Midstream Partners, LP owns, operates, acquires and develops midstream assets in the Appalachian Basin. The Company provides substantially all of its natural gas transmission, storage and gathering services under contracts with fixed reservation and/or usage fees. The Company focuses its operations in the Marcellus Shale fairway in southern Pennsylvania and northern West Virginia. It provides midstream services to EQT Corporation in the Appalachian Basin across 22 counties in Pennsylvania and West Virginia through its two primary assets: its transmission and storage system, which serves as a header system transmission pipeline, and its gathering system, which delivers natural gas from wells and other receipt points to transmission pipelines.

Equitrans Transmission and Storage System

As of December 31, 2011, the Company�� transmission and storage system included an approximately 700 mile FERC-regulated interstate pipeline system that connects to five interstate pipelines and multiple distribution companies, and it is supported by 14 associated natural gas storage reservoirs with approximately 400 million cubic feet per day of peak withdrawal capability and 32 billion cubic feet of working gas capacity. As of December 31, 2011, its transmission assets had total throughput capacity of approximately 1.0 trillion British thermal units per day.

Equitrans Gathering System

The Company�� gathering system consists of approximately 2,100 miles of FERC-regulated low-pressure gathering lines that have multiple delivery interconnects with its transmission and storage system and a gathering and interstate pipeline system owned and operated by Dominion Transmission, Inc.

Advisors' Opinion:
  • [By Matt DiLallo]

    Unfortunately for XTO Energy, there was one small and, unbeknownst to anyone, unresolved matter. You see, LINN had a contract to sell its gas through a unit of Dominion Resources (NYSE: D  ) , which was gathering the gas in its system. However, LINN's gas wasn't up to the system's standards, so it began to look for another gatherer and it approached Equitrans, which is now part of EQT Midstream Partners (NYSE: EQM  ) but formerly was a unit of EQT Corp. (NYSE: EQT  ) -- they talked, but nothing was signed. However, an EQT employee later that year thought that it had and began crediting gas to the wrong company.

  • [By Michael Flannelly]

    Goldman Sachs analysts started coverage on EQT Midstream Partners LP (EQM) early on Monday, giving the oil and natural gas distribution company a bullish rating due to its low-risk cash flows.

    The analysts rate EQM as “Buy” and see shares reaching $59. This price target suggests a 22% upside to the stock’s Friday closing price of $48.28.

    Goldman Sachs analyst Theodore Durbin said, “EQM’s FERCregulated pipeline and storage assets offer stable, low-risk fee-based cash flows supported by firm long-term contracts. A robust production outlook in the Marcellus and meaningful inventory of dropdown assets at the parent enhances distribution growth visibility. EQM has a low cost of capital, no debt outstanding, high liquidity and an aligned sponsor that should bolster the partnership�� multi-year double-digit distribution growth outlook.”

    EQT Midstream Partners shares were inactive during pre-market trading on Monday. The stock is up 54.99% year-to-date.

10 Best Transportation Stocks To Own Right Now: FedEx Corporation(FDX)

FedEx Corporation provides transportation, e-commerce, and business services in the United States and internationally. It operates in four segments: FedEx Express, FedEx Ground, FedEx Freight, and FedEx Services. The FedEx Express segment offers various shipping services for the delivery of packages and freight. This segment also provides international trade services specializing in customs brokerage, and ocean and air freight forwarding services; customs clearance services, as well as global trade data, an information tool that allows customers to track and manage imports; and international trade advisory services, including assistance with the customs-trade partnership against terrorism program, as well as publishes customs duty and tax information in various customs areas. In addition, it offers supply chain solutions, including critical inventory logistics, transportation management, fulfillment, and fleet services. The FedEx Ground segment provides business and reside ntial ground package delivery services. It primarily serves customers in the small-package market in North America. The FedEx Freight segment offers less-than-truckload freight services, as well as freight-shipping services. As of May 31, 2010, this segment operated approximately 60,000 vehicles and trailers from a network of 492 service centers. The FedEx Services segment provides sales, marketing, information technology support, and customer service support services; and access to copying and digital printing through retail and Web-based platforms, signs and graphics, professional finishing, computer rentals, and a range of ground shipping and time-definite express shipping services. The company was founded in 1971 and is headquartered in Memphis, Tennessee.

Advisors' Opinion:
  • [By Laura Brodbeck]

    Next week, investors will be waiting for several key earnings reports including Oracle Corporation (NASDAQ: ORCL), Nike, Inc. (NYSE: NKE), BlackBerry (NASDAQ: BBRY), Rite Aid Corporation (NYSE: RAD), and FedEx Corporation (NYSE: FDX).

  • [By Paul Ausick]

    As of December 17, The Boeing Co. (NYSE: BA) had booked a net total for 1,074 new planes in 2013, compared with a net total of 1,314 new orders reported by archrival Airbus. On Friday, Boeing added an order for 21 new 777X aircraft from Cathay Pacific Airways, on top of an order for two new 767 freighters from FedEx Corp. (NYSE: FDX).

  • [By Arjun Sreekumar]

    Another major freight services company, FedEx (NYSE: FDX  ) , is also investigating the benefits of natural gas. The company is currently running tests ��using two LNG-powered and two CNG-powered trucks ��to determine whether or not to convert more of its 90,000 motorized vehicles to run on the cleaner-burning fuel. The company's chairman and CEO, Frederick W. Smith, said he expects 5%-30% of long-distance trucks to run on CNG or LNG over the next decade, as costs fall and the number of fueling stations rises. �

  • [By Caroline Chen]

    Investor Dan Loeb�� decision to take a stake in FedEx Corp. (FDX) is poised to heighten scrutiny of the role played by Fred Smith, who has run the airfreight company since its founding more than 40 years ago.

10 Best Transportation Stocks To Own Right Now: KNOT Offshore Partners LP (KNOP)

KNOT Offshore Partners LP, incorporated on February 21, 2013, is a limited partnership formed to own, operate and acquire shuttle tankers under long-term charters. Its initial fleet of shuttle tankers contribute to the Company by Knutsen NYK Offshore Tankers AS (KNOT), which is jointly owned by TS Shipping Invest AS, (TSSI), and Nippon Yusen Kaisha (NYK). NYK is a Japanese public company with a fleet of approximately 800 vessels, including bulk carriers, containerships, tankers and specialized vessels. The Company is a holding entity and is conduct its operations and business through subsidiaries KNOT is an independent owner of crude oil shuttle tankers. Its general partner is KNOT Offshore Partners GP LLC. In August 2013, KNOT Offshore Partners LP's wholly owned subsidiary KNOT Shuttle Tankers AS completed its acquisition of all interests in Knutsen Shuttle Tanker 13 AS that owns and operates the Carmen Knutsen from KNOT Offshore Tankers AS.

The Company's initial fleet consists of four shuttle tankers, which are vessels designed to transport crude oil and condensates from offshore oil field installations to onshore terminals and refineries. The shuttle tankers include , Fortaleza Knutsen, Recife Knutsen, Bodil Knutsen and Windsor Knutsen. Its shuttle tankers are equipped with loading systems and dynamic positioning systems that allow the vessels to load cargo safely and reliably from oil field installations, even in harsh weather conditions.

Advisors' Opinion:
  • [By Robert Rapier] There were a half a dozen initial public offerings (IPOs) by master limited partnerships in the first half of the year, and all but one are now in the green while one has nearly doubled in value.

    The first MLP IPO of 2013 debuted on Jan. 15. USA Compression Partners (NYSE: USAC), which I mentioned in last week’s issue, provides compression services for the oil and gas industry. Units have advanced 36 percent since the IPO, and at the current price yield 7.3 percent.

    The day after the USA Compression Partners IPO, CVR Refining (NYSE: CVRR) made its debut.  CVRR was spun off from CVR Energy (NYSE: CVI), and both companies remain majority-owned by Carl Icahn. CVR Refining’s primary assets are two refineries located in Kansas and Oklahoma with a combined processing capacity of approximately 185,000 barrels per day (bpd). These refineries are strategically located near the major Cushing, Oklahoma shipment and storage hub, with easy access to discounted feedstock from the nearby Permian basin, as well as the Bakken shale and Canadian oil sands.

    But refiners have struggled with diminished margins in 2013 because of a much lower Brent-WTI differential. After the recently concluded second quarter, CVRR declared a distribution of $1.35 per unit, bringing its per-unit distributions for the first half of the year to $2.93. At the same time, CVR Refining lowered its annual distribution target to a range of $4.10 to $4.80 per unit. This was lower than the outlook issued in March, when it foresaw annual distributions of $5.50 to $6.50. CVRR units slid on the news, and are presently trading slightly below the $25 IPO price. The lower end of the revised forecast implies distributions of $1.17 per unit in the second half of the year, for a forward annualized yield of 10 percent based on the recent $23.50 unit price.

    SunCoke Energy Partners (NYSE: SXCP) was the third IPO to debut during a very busy third week of January. SXCP is the first M
  • [By Aimee Duffy]

    1. KNOT Offshore Partners (NYSE: KNOP  )
    Ever wonder how the oil gets from the offshore rig to the onshore refinery? Sometimes there's a pipeline, and sometimes there are shuttle tankers, like the ones owned and operated by KNOT Offshore.

10 Best Transportation Stocks To Own Right Now: China Metro-Rural Holdings Limited(CNR)

China Metro-Rural Holdings Limited, through its subsidiaries, primarily engages in the development and operation of agricultural logistics and trade centers in northeast China. It also involves in purchasing, processing, assembling, merchandising, and distributing pearls and jewelry products. The company markets its pearls and jewelry products to wholesale distributors and mass merchandisers in Europe, the United States, Hong Kong, and other parts of Asia. In addition, it develops, sells, and leases residential and commercial properties in Hong Kong and the People?s Republic of China. The company is based in Tsimshatsui, Hong Kong.

Advisors' Opinion:
  • [By Katie Brennan]

    Canadian National Railway Co. (CNR) added 0.9 percent to C$104.93 and Canadian Pacific Railway Ltd. rose 1.7 percent to C$131.73.

    Niko Resources surged 3.4 percent to $8.64 after the company entered an agreement for a $60 million loan that will be funded by a group of institutional investors. Net proceeds from the loan will be used to fund working capital requirements.

Sunday, April 27, 2014

How to Get in the Game and Profit

A few weeks ago, I told you a story about a woman who took my advice and used it to overcome her fear of investing.

As it turns out, it was an incredibly popular column.

Reader Robert from Vancouver wrote:

Thanks Shah for trying to provide some financial education.

There is a real and urgent need to teach people at least the basics of investing, the economy, and business.

And I wholeheartedly agree.

That's why I wanted to come back and build on the advice I originally gave you.

You see, once you make a decision to start investing, the next step is to make a commitment to become successful.

And today I'm going to show you how to make that next step...

To Be Successful, You Have to Put on Trades

In a nutshell, the advice I gave in my March 27 column was:

Start by taking positions in companies you know something about. It doesn't matter if you like or hate it. Just that you know enough about the company's products, services, whatever they do, so the stock's ups and downs make sense to you.

Once you pick a stock, you always start the same way. You put on the trade.

Never think that your trade, or your position, is an investment. It isn't. It is a trade.

You can get out of it at any time.

If it turns into a brilliant pick, your trade will turn into an "investment" because it's worth holding onto.

But to become a successful investor you have to start by putting on trades.

You can't make money watching from the sidelines. But you also can't be a deer in the headlights either. You can't go into a trade and think it's an investment and you're stuck with it when it goes against you. It's a trade!

And the reality is that some of your trades will be losers...

That means you will get out of positions with small losses. It's part of the game. You will have some losses but they will be monumentally overwhelmed by the trades that will make great money. And the ones that keep going up and maybe pay you dividends will become the "core" of your investment portfolio.

And that's your ultimate goal. You want to create an investment plan that leads to financial freedom.

Psychology and Perception Are More Important Than Data and Facts

One of the reasons I say that you don't need to be an expert on any company, or on any stock, is that no matter how much homework you do, no matter how much analysis you do, what makes perfect sense on paper may have nothing to do with how your stock trades.

When you watch your stock going up and down, you begin to understand the "psychology" of other investors - what they're looking at, how they interpret news and data.

You're one person with one position. There are millions of people like you watching that same stock. Collectively, their perception of news and data and the psychology of their fear and greed ultimately motivate them to take action, which moves the stock.

I can't tell you how many times I've done copious amounts of research and been absolutely confident that I was putting on a winning trade, only to have my head handed to me because other traders' perception of something that came along (it could be out of nowhere) was interpreted as a reason to sell the stock.

My saying - and I live by this - is:

Money moves markets, but psychology moves money.

What I'm saying is: Go ahead and do your homework. But your knowledge of your stock, or your position, has to include your understanding about how other investors perceive the stock and its likelihood to go up or down.

Market psychology is everything. I can trade anything, any stock, any bond, any commodity, any derivative, anything, because I trade on OPP - Other People's Psychology.

It's not easy reading the market's psychology, or the perception the market has about a stock's prospects. But it's not hard either.

First of all, understand that there are two ways to trade psychology.

You go with the flow.

You go against the flow.

I do both, and quite successfully.

Going with the flow is all about the "trend."

The Trend Is Your Friend

Live by that and you will make a lot of money.

In terms of market psychology I always look for the big picture first. What is the big trend? Is the market (we're talking about stocks) in an uptrend or downtrend?

If it's an uptrend I want to be buying stocks. If it's a downtrend I want to be shorting.

Always go with the flow by trading within the big trends.

After all, if the market is going higher, why would you fight it? You don't, you ride it.

Of course, there are nuances in following the big trend. The general market may be going higher but maybe the stock you want to buy falls in an industry that's not going along with the big trend. You have to be careful about that.

That's where going against the flow might come into play.

I make a lot of money following the trends and riding them. But, sometimes I go against the trend.

The reasons to go against the big trend start with the big trend. Maybe you see it stalling out. Maybe you think it's about to turn around and go the other way. It's at these junctures that going against the trend, in measured fashion, can be very profitable.

If I think the psychology has changed and the general market is turning bearish, but the market has still been holding onto its gains, such that I see selective selling, or profit-taking, I will put on a counter-trend position.

If you put on counter-trend positions at inflection points, meaning where the market seems like it could change, you aren't taking a stupid risk. Instead, you are taking a shot that you can get ahead of the bigger shift in psychology.

What's critical is that whenever you take a counter-trend position, you don't "get married" to the position.

You're going against the trend, which you don't generally want to do. But because picking tops and bottoms can be extremely lucrative (and trying to do that exponentially ups your learning curve), it's worth the risk. Again, you only do that when you think you sense a change in the trend.

If I take a counter-trend position and the trade starts out against me, I get out just as the big trend reconvenes its footing and continues. I will lose a little and move on.

Here's another way to play a counter-trend within a bigger trend: Buy that stock you wanted to buy but didn't because its industry group wasn't following the big trend higher.

At some point, when I think that stock and its industry may be out of favor enough, I'd consider buying in. Why? Because if the big trend is still up and I think it's strengthening, then buying an out-of-favor stock that has already gone down (but is a fundamentally good company, not some crazy stock) isn't as risky as it seems.

And if you've done your homework and like the stock but have been surprised that it has gone down in a rising market, then you'll know instinctively if it has gone down enough to make it a good "value" in the rising market. That's not a risky position.

I can't impress upon you enough that you know more than you think. You have to trust yourself. Use your own knowledge of how people react to gauge mass psychology, which sometimes is mass delusion. But that's another lesson.

So, I'll say it again. Tune yourself into the psychology of the market. The psychology of other traders and investors, of what they are reacting to, of their fear and greed.

Perception is reality when it comes to how money reacts.

Saturday, April 26, 2014

AbbVie Beats Earnings, Gilead Sciences Benefits

AbbVie (ABBV) released solid financial results today, but Gilead Sciences (GILD) seems to be getting the benefit today.

AbbVie reported a profit of 71 cents a share, beating forecasts for 68 cents, on sales of $4.56 billion, topping the Street consensus of $4.56 billion.

On it’s conference call, AbbVie signaled that it didn’t intend to get into a hepatitis-C treatment pricing war. UBS analyst Matthew Roden says that’s good news for Gilead Sciences:

AbbVie’s 1Q call just ended, on which it reiterated that pricing is “NOT our strategy” in HCV. Our HCV thesis on pricing has been that AbbVie will list price at parity, and that initial discounting would be limited between two players. We do expect that gross-net will widen over time with additional market entrants, but we do not expect significant price erosion in the near to mid-term. Secondly, we’ve modelled the HCV as a long-lived market, peaking globally at $26bn in 2022. AbbVie also expects a “cadence” of treatment to draw out the market over the long term. In our view, AbbVie’s stance is consistent with our constructive view on HCV, and specifically addresses investor pushback on [Gilead Sciences].

Top Information Technology Stocks To Invest In Right Now

Shares of AbbVie are little changed at $49.30 at 2:03 p.m., while Gilead Sciences has gained 0.7% to $74.60. Gilead’s gain is particularly impressive considering that the iShares Nasdaq Biotechnology ETF (IBB) has dropped 2.1% to $224.88 today.

Thursday, April 24, 2014

7 (Civilian) Planes That Made Boeing Great

Beware: I suspect this article will please precisely no one. Consider yourself forewarned.

After two weeks that have seen two Boeing (NYSE: BA  ) planes left burning on the tarmac, I've been asked to remind investors of the bigger picture at Boeing -- to pen a piece on the seven planes that made Boeing great.

Of course, boiling down the history of a century-old plane builder to just seven important models must be an exercise in triage. Do we limit our choices to Boeing qua Boeing, or do McDonnell-Douglas (or even just Douglas) birds deserve to roost among these rankings? (Sure. Why not?) Do we count military warplanes, in addition to civilian airliners? (No. At least not in today's column.) And how far back in time shall we search for the roots of Boeing's greatness, and how far into the future dare we guess its success may reach?

The only certainty is this: Anyone who knows Boeing at all is going to disagree with at least some of these choices. So be it. Without further ado, here are my nominations for the seven planes that made Boeing a great company -- and that give us some assurance this company has the staying power to remain great despite its recent setbacks.

Boeing 80


Boeing 80, Source: Boeing.

First flown in 1928, the Model 80 was the plane that got Boeing off the ground. It was the company's first airplane built specifically for passenger transport, carrying first a dozen passengers, then later upgraded to the Model 80A-1, which could carry 18. It was the plane Boeing built to compete with rival passenger aircraft from Fokker and (if you can believe it) Ford (NYSE: F  ) , and it eventually became the first plane with a stewardess on board to hand out refreshments (a registered nurse, Ellen Church, landed the first stewardess berth in 1930).

In its reconfigured 80A-1 iteration, the Model 80 sported an 80-foot wingspan and could fly as far as 460 miles.

Boeing 314 Clipper


Boeing 314, Source: Boeing.

Perception is a powerful thing. When selling an airplane to an airline, there can hardly be a more potent marketing tool than a line like this: "And did you know this is the plane the president picked to fly on?"

Well, in 1943, in the middle of World War II, President Franklin D. Roosevelt flew to Casablanca aboard the Dixie Clipper, a Boeing 314 -- making the 314 the effectively the very first "Air Force One." (They didn't call it that, of course. Not least because at the time, the U.S. didn't actually have an Air Force.)

The Boeing 314 enjoyed some commercial success as well. It was first flown in 1938, and 12 of the planes were built before WWII broke out. Designed to spec for Pan American World Airways as a "flying boat" capable of carrying passengers to Europe, the 314 could carry 74 passengers in style and boasted a flight range of 3,500 miles. With a wingspan of 152 feet, the deep-chested 314 was more than twice as big as the Model 80.

Douglas DC-3


Douglas DC-3, Source: Boeing.

Sometimes, great mergers create greater companies. If you've ever wondered why McDonnell Aircraft bought Douglas Aircraft in 1967, or why Boeing merged with McDonnell Douglas 30 years later, the answer can be summed up in one hyphenated word: DC-3.

It wasn't as big as the Boeing 314, with a smaller wingspan and a shorter range. Yet Boeing modestly calls the DC-3, first flown in 1935, "the greatest airplane of its time," and perhaps "the greatest of all time." Many people agree. Originally built for American Airlines (now US Airways (NYSE: LCC  ) ), the plane soon gained a fan in United Airlines (now United Continental (NYSE: UAL  ) ) -- and then it went on to win sales contracts at nearly three dozen airlines and to (in alliance with its DC-2 predecessor) capture more than 90% of the air-passenger market. The DC-3 carried 28 passengers, or slept 14, which doesn't sound like a lot in today's terms. But it was the first plane capable of carrying enough passengers, and carrying them fuel-efficiently enough, to earn its airline owners a profit.

One testament to the plane's quality? Hundreds of DC-3s are still flying today, nearly four score years after the plane was first built.

Boeing 707


Boeing 707, Source: Boeing.

Built around the bones of the KC-135 military aerial refueling tanker in 1957, the Boeing 707 got off to a troubled start. Not all that unlike with the 787 today, Boeing made a lot of big bets on the 707, and these bets came to define the company -- and the industry, in time.

For example, the 707 standardized Boeing and industry practice of putting the passenger door on the left side of the plane, and installing doors both fore and aft. Boeing also gambled big on customizing the base model plane (130-foot wingspan, 3,000-mile range) to the requirements of multiple customers. It built longer-range models for far-off Australia's Qantas Airways, and it tweaked the plane to accept bigger engines for high-altitude flights among South American airlines. That was quite a change from the old practice of drawing up entirely new airplanes at the request of individual customers such as American and United.

Such tweaks cost some money, sure. But they also helped Boeing grab market share from rival Douglas Aircraft. Ultimately, Boeing sold 856 of the planes.

Boeing 737


Boeing 737, Source: Boeing.

Forty-six years young and still going strong, our next entree on the Boeing's best planes-list is a no-brainer: the Boeing 737. 93.7 feet long, and with a 93-foot wingspan, the original 737 was nicknamed "the square" for its nearly equal measurements. It flew 1,150 miles on a full tank of gas and carried as many as 107 passengers. Later versions, running up through today's 737 Next Generation and 737 MAX iterations, can carry as many as twice that number.

Currently en route to delivering well over 10,000 planes, with more than 7,000 already in the hands of its customers, the 737 is the most successful commercial airplane ever built. Now in its fifth decade of production, the 737 remains so popular that Boeing quite literally cannot build the planes fast enough to keep up with demand.

Boeing 747


Boeing 747, Source: Boeing.

Boeing designed and built the world's first jumbo jet in just 16 months, and then got it airborne in 1969. Perhaps Boeing's most iconic airplane, the first Boeing 747 stood six stories tall and weighed nearly 370 tons. It was so big that Boeing had to construct an entirely new factory to build it. The existing workplaces just didn't fit.

For nearly 40 years, it was the world's biggest passenger jet, carrying as many as 550 passengers on flights as long as 6,000 miles. Needless to say, it's still flying today. In fact, just last week Boeing sold two more of them. (Freighter versions).

Boeing 777


Boeing 777, Source: Boeing.

Last but not least -- and really, not even last -- we'll end this list with the plane that inspired it: the Boeing 777, which crash-landed and caught fire at San Francisco International Airport last weekend -- yet was so well built that it managed to keep all but two passengers alive through the crash, out of hundreds aboard.

How great is the 777, and how helpful is its reputation to Boeing? It's great enough that last week's crash was only the second significant accident recorded in the Triple-7's 18-year history. Great enough that, according to famed Capt. Chesley "Sully" Sullenberger, last weekend was the only recorded instance in which a passenger aboard a 777 died. And it's great enough to have persuaded Boeing's customers to line up and buy 1,100 777s over the years. 

The biggest twin-engine commercial jet in the world, the 777 was Boeing's first plane to be designed entirely on computer using 3-D graphics. It sports wings spanning nearly 200 feet, a range upwards of 8,000 miles, and capacity to haul up to 440 passengers more than one-third of the way around the earth before needing to refuel.

Foolish takeaway
Boeing's planes have, and Boeing's stock has, stood the test of time -- 97 years, to be precise. Does all this prove conclusively that Boeing stock should be bought today, at a 19 P/E ratio? Maybe, maybe not. But before you count Boeing out over a couple of mishaps, remember -- its biggest rival today, Airbus parent EADS (NASDAQOTH: EADSY  ) , costs more than 25 times earnings. And EADS has only been around since 2000.

Seems to me that investors who are valuing Boeing at a discount to its less-proven rival are doing Boeing a disservice.

The Economist compares this disruptive invention to the steam engine and the printing press. Business Insider says it makes up "the next trillion-dollar industry." And everyone from BMW to Nike to the U.S. Air Force is already using it every day. Watch The Motley Fool's shocking video presentation today to discover the garage gadget that's putting an end to the "Made in China" era ... and learn the investing strategy we've used to double our money on these three stocks. Click here to watch now!

Wednesday, April 23, 2014

Top Medical Stocks To Buy Right Now

As the April 15 tax deadline fast approaches, you probably have questions. Fortunately, we have answers. Every day until April 15, members of the American Institute of Certified Public Accountants have agreed to answer selected tax questions from USA TODAY readers. Submit your questions to jwaggoner@usatoday.com.

Q: I have parents living with me at home who have retired. They both receive Social Security and do not work. Their total Social Security is not more than $600 a month. They have no means to support themselves with that much income monthly; hence, I take care of them. I have been claiming them as dependents on my taxes. I wanted to make sure this was legal in the eyes of IRS. If they were to get sick and get hospitalized, would I be responsible for their medical bills if I have been claiming them as dependents and Medicare does not cover something for whatever reason?

Top Medical Stocks To Buy Right Now: Stemline Therapeutics Inc (STML)

Stemline Therapeutics, Inc. (Stemline), incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds global marketing rights. The indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia (AML). The indications for SL-701, a synthetic peptide vaccine, are pediatric and adult brain cancer. It has a platform, StemScreen, for the discovery of CSC-targeted compounds, from which it has discovered or validated several of its clinical and preclinical product candidates. Stemline�� StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.

SL-301 is a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types. SL-101 is a monoclonal antibody-based (mAb -based) compound that targets CD123 and has shown in vitro activity against certain hematologic cancers. SL-201 is a small molecule active against certain hematologic and solid tumor types. SL-601 is a mAb-based compound that targets a cell surface marker on bladder CSCs, which is also expressed on a variety of other solid tumor types. It has also in-licensed certain intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened and Patched.

SL-401 - An IL-3R-Directed Compound Targeting Cancer Stem Cells and Tumor Bulk

SL-401 is a clinically active biologic-drug conjugate consisting of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor (IL-3R), which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancers, including AML. SL-401 has demonstrated preclinical in vit! ro and in vivo activity against both leukemia blasts (which includes tumor bulk) and CSCs of a range of human leukemia cell lines and primary leukemia cells from patients.

SL-701

SL-701 is a clinically active synthetic peptide vaccine that targets several epitopes on CSCs and tumor bulk of brain cancer. In two completed Phase 1/2 clinical trials, SL-701 demonstrated single agent anti-tumor activity in pediatric patients with newly diagnosed brainstem glioma (BSG) and other high-grade gliomas (HGGs) and in adult patients with refractory or recurrent GBM, and other HGGs.

StemScreen-1

StemScreen-1 is a drug discovery platform designed to identify CSC-targeted compounds based on the isolation of CSCs and evaluation of CSC gene expression profiles. CSCs are isolated from primary tumor tissue or cell lines, and then subjected to gene expression analysis using a variety of technologies, including microarray. A control tissue, such as normal bone marrow is analyzed as a comparator against the gene expression profile of the isolated CSCs. These data are then interfaced with an information base of compounds and their mechanisms of action (that is which gene products and pathways they impact). It has utilized StemScreen-1 to discover a number of its preclinical drug candidates. These include SL-201, SL-301, and SL-601. In addition, SL-401 demonstrated activity against CSCs as determined by both an in vitro colony formation and in vivo animal implantation assay, thereby validating certain StemScreen-1 anti-CSC assays.

StemScreen-2

StemScreen-2 is a high throughput drug discovery platform it is developing to discover anti-CSC compounds. StemScreen-2 utilizes a cell-based assay that can track and follow CSCs in their natural state during high throughput screening. In particular, StemScreen-2 utilizes a CSC-specific promoter linked to a reporter as a method for identifying and following CSCs in their native environment of surrounding tumor b! ulk. In t! his way, StemScreen-2 enables the identification of compound hits, in a high throughput manner, with anti-CSC activity.

The Company competes with Boston Biomedical, Inc., Eclipse Therapeutics, Inc., OncoMed Pharmaceuticals, Inc., Verastem, Inc., Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, Dainippon Sumitomo Pharma Co. Ltd., Geron Corp., GlaxoSmithKline plc, ImmunoCellular Therapeutics, Ltd, Macrogenics Inc., Amgen, Inc., Pfizer Inc., Roche Holding AG, Sanofi U.S. LLC., Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Eisai Co. Ltd., Celator Pharmaceuticals, Inc., Merck & Co., Inc., Eisai Co., Inc., Roche Holding AG, Novartis AG and Celldex Therapeutics, Inc.

Advisors' Opinion:
  • [By Keith Speights]

    Best-performing biotech IPO
    Stemline Therapeutics� (NASDAQ: STML  ) has only traded publicly this year, but what a year it's been. The stock's performance ranks Stemline as the best-performing biotech IPO so far in 2013. This week has been pretty good also, with shares moving up by 28%.

Top Medical Stocks To Buy Right Now: Pharmacyclics Inc (PCYC)

Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.

As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.

Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).

PCI-27483 Factor VIIa Inhibitor

The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.

Factor VIIa PCI-27483 Clinical Development Update

A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.

A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.

Advisors' Opinion:
  • [By Ben Levisohn]

    [The] sell-off in recent days was broad based and…affecting stocks in direct relationship to their volatility and expected duration of negative cash flow. Small and mid cap stocks were most affected (especially post-IPO stocks), and those with major uncertain events looming (MDVN) or with significant revenue upside already built into valuation (PCYC) were among the most severely affected. However, nothing changed in the environment to suggest that those events were any more or less likely to have positive outcomes yesterday, or to suggest that revenue potential was any more or less likely to be achieved than was previously expected.

  • [By Sean Williams]

    What's perhaps more remarkable is the fact that Pharmacyclics (NASDAQ: PCYC  ) has three of those 23 approved breakthrough therapy designations for its lead experimental drug, ibrutinib. Ibrutinib, which is also licensed to Johnson & Johnson (NYSE: JNJ  ) subsidiary Janssen Pharmaceuticals, was designated as a breakthrough therapy for patients with chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom's macroglobulinemia. The big potential indication here is CLL, which is the most common adulthood leukemia and occurs in 113,000 people in the U.S. By comparison, MCL diagnoses number about 5,000 each year.

  • [By John McCamant]

    The company��hich we consider conservative among biotech stocks��s Pharmacyclics (PCYC). Its pill is also expected to be approved for a much larger B-cell cancer market, chronic lymphocytic leukemia (CLL), by the end of February.

Top 10 Medical Companies To Buy Right Now: Myriad Genetics Inc (MYGN)

Myriad Genetics, Inc. (Myriad) is a molecular diagnostic company. The Company is focused on developing and marketing predictive medicine, personalized medicine and prognostic medicine tests. It performs all of its molecular diagnostic testing and analysis in its own reference laboratories. These technologies include the cornerstone technologies of biomarker discovery, high-throughput deoxyribo nucleuc acid (DNA) sequencing, ribo nucleic acid (RNA) expression and multiplex protein analysis. The Company uses this information to guide the development of new molecular diagnostic tests that are designed to assess an individual's risk for developing disease later in life (predictive medicine), identify a patient's likelihood of responding to drug therapy and guide a patient's dosing to ensure optimal treatment (personalized medicine), or assess a patient's risk of disease progression and disease recurrence (prognostic medicine).

As of June 30, 2012, the Company had launched nine commercial molecular diagnostic tests. The Company markets these tests through its own approximate 385-person sales force in the United States. The Company also markets its BRACAnalysis, COLARIS, and COLARIS AP tests through its own European sales force and have entered into marketing collaborations with other organizations in selected Latin American, European and Asian countries. The Company also generates revenue by providing companion diagnostic services to the pharmaceutical, and biotechnology industries and medical research institutions utilizing its multiplexed immunoassay technology.

Molecular Diagnostic Tests

The Company's molecular diagnostic tests are designed to analyze genes, their mutations, expression levels and proteins to assess an individual's risk for developing disease later in life, determine a patient's likelihood of responding to a particular drug, assess a patient's risk of disease progression and disease recurrence and measure a patient's exposure to drug therapy to ensu! re optimal dosing and reduced drug toxicity. The Company's BRACAnalysis test is a analysis of the BRCA1 and BRCA2 genes for assessing a woman's risk of developing hereditary breast and ovarian cancer. BRACAnalysis accounted for 81.7% of the Company's total revenue during the fiscal year ended June 30, 2012. Its The Company's COLARIS test is an analysis of the MLH1, MSH2, MSH6 and PMS2 genes for assessing a person's risk of developing colorectal cancer or uterine cancer.

The Company's COLARIS AP test detects mutations in the APC and MYH genes, which cause a colon polyp-forming syndrome known as Familial Adenomatous Polyposis (FAP), a more common variation of the syndrome known as attenuated FAP, and the MYH-associated polyposis signature (MAP). The Company's MELARIS test analyzes mutations in the p16 gene to determine genetic susceptibility to malignant melanoma. The Company's OnDose test is a nanoparticle immunoassay that is designed to assist oncologists in optimizing 5-FU (fluorouracil) anti-cancer drug therapy in colon cancer patients on an individualized basis. The Company's PANEXIA test is a comprehensive analysis of the PALB2 and BRCA2 genes for assessing a person's risk of developing pancreatic cancer later in life. The Company's PREZEON test is an immunohistochemistry test that analyzes the PTEN gene and assesses loss of PTEN function in many cancer types.

The Company's Prolaris test is a 46-gene molecular diagnostic assay that assesses whether a patient is likely to have a slow growing, indolent form of prostate cancer that can be safely monitored through active surveillance, or a more aggressive form of the disease that would warrant aggressive intervention, such as a radical prostatectomy or radiation therapy. The Company's TheraGuide 5-FU test analyzes mutations in the DPYD gene and variations in the TYMS gene to assess patient risk of toxicity to 5-FU (fluorouracil) anti-cancer drug therapy.

Companion Diagnostic Services and Other Revenue

! Through M! yriad RBM Inc., the Company provides biomarker discovery and companion diagnostic services to the pharmaceutical, biotechnology, and medical researches industries utilizing its multiplexed immunoassay technology. The Company's technology enables the Company to screen large sets of clinical samples from both diseased and non-diseased populations against the Company's menu of biomarkers. The Company's companion diagnostic services consist of Multi-Analyte Profile (MAP), Multiplexed Immunoassay Kits and TruCulture.

The Company has compiled a library of over 550 individual human and rodent immunoassays for use in its multi-analyte profile (MAP) testing services. The Company has also developed RodentMAP, a panel for use in pre-clinical animal studies and OncologyMAP, which measures cancer-related proteins to assists researchers accelerate the pace of discovery, validation and translation of cancer biomarkers for early detection, patient stratification and therapeutic monitoring. The Company has developed multiplexed immunoassay kits that enable its customers to leverage its technology services with their in-house capabilities. The Company's internally developed multiplexed immunoassay kits include all of the components necessary for a customer to perform a test on their own Luminex instrument. TruCulture is a simple, self-contained whole blood culture that can be deployed to clinical sites around the world for acquiring cell culture data without specialized facilities or training.

Advisors' Opinion:
  • [By Monica Gerson]

    Breaking news

    Loews (NYSE: L) reported a 59% rise in its third-quarter earnings. Loews posted a quarterly profit of $282 million, or $0.73 per share, versus a year-ago profit of $177 million, or $0.45 per share. To read the full news, click here. BankUnited (NYSE: BKU) announced today the commencement of an underwritten offering of 9,000,000 shares of its common stock by certain of its existing stockholders, subject to market and other conditions. To read the full news, click here. Liberty Global (NASDAQ: LBTYA) announced today an agreement to sell substantially all of its international content division Chellomedia to AMC Networks (NASDAQ: AMCX).To read the full news, click here. Myriad Genetics (NASDAQ: MYGN) today announced that validation data for the Myriad myPlan Lung Cancer test showed that it significantly predicted patients' risk of death from early-stage lung adenocarcinoma within five years of being diagnosed. To read the full news, click here.

    Posted-In: Bank of America US Stock FuturesNews Eurozone Futures Global Pre-Market Outlook Markets

  • [By Ben Levisohn]

    Shares of Myriad Genetics (MYGN) have plunged this morning after a U.S. agency said it would pay less for its breast-cancer tests.

    The Wall Street Journal has the details:

    The price of a popular genetic test that predicts women’s risk of breast cancer is likely to drop in the New Year after the agency that administers Medicare benefits said it would slash its reimbursement rate for the test by half.

    The rate cut goes into effect on Jan. 1, 2014, with consequences for genetic-testing companies, particularly�Myriad Genetics�Inc., the dominant supplier of screenings for mutations in the genes known as BRCA1 and BRCA2. Medicare will pay a maximum of $1,440 for the BRCA test, a 48.5% decline from the rate of $2,795 it paid in 2013, according to a notice published Friday afternoon on the website of the Centers for Medicare and Medicaid Services.

    The announcement comes just months after the Supreme Court said that Myriad couldn’t patent the BRCA genes and allowed companies like Quest Diagnostics (DGX) to offer its own tests, the Wall Street Journal says.

    JPMorgan’s Tycho Peterson and team call the decisions a “significant negative” for Myriad Genetics:

    We view this confirmation of the rate cut as a significant negative for MYGN as the company will have a difficult time explaining why CMS believes the BRCA test should cost less than half of MYGN�� list price ($4,040).

    Primary question is how quickly this will impact private payors. With increased competition coming to the market at significantly lower prices than MYGN, we expect payors will begin to influence physicians to use competitive tests, while leaving open the option for patients to use MYGN�� test if they want to pay the additional cost (+$1,500) out of pocket. In our prior physician survey (found here), all 25 physicians surveyed were willing to convert away from MYGN for a competitive product and 76% viewed price as a ��/li>

Top Medical Stocks To Buy Right Now: Johnson & Johnson(JNJ)

Johnson & Johnson engages in the research and development, manufacture, and sale of various products in the health care field worldwide. The company operates in three segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics. The Consumer segment provides products used in baby care, skin care, oral care, wound care, and women?s health care fields, as well as nutritional, over-the-counter pharmaceutical products, and wellness and prevention platforms under the brands of JOHNSON?S, AVEENO, CLEAN & CLEAR, JOHNSON?S Adult, NEUTROGENA, RoC, LUBRIDERM, DABAO, LISTERINE, REACH, BAND-AID, CAREFREE, STAYFREE, SPLENDA, TYLENOL, SUDAFED, ZYRTEC, MOTRIN IB, and PEPCID AC. The Pharmaceutical segment offers products in various therapeutic areas, such as anti-infective, antipsychotic, contraceptive, dermatology, gastrointestinal, hematology, immunology, neurology, oncology, pain management, and virology. Its principal products include REMICADE for the treatment of immune me diated inflammatory diseases; STELARA for the treatment of moderate to severe plaque psoriasis; SIMPONI, a treatment for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; VELCADE for the treatment of multiple myeloma; PREZISTA and INTELENCE for treating HIV/AIDS patients; NUCYNTA for moderate to severe acute pain; INVEGA SUSTENNAtm for the acute and maintenance treatment of schizophrenia in adults; RISPERDAL CONSTA for the management of bipolar I disorder and schizophrenia; and PROCRIT to stimulate red blood cell production. The Medical Devices and Diagnostics segment primarily offers circulatory disease management products; orthopaedic joint reconstruction, spinal care, and sports medicine products; surgical care, aesthetics, and women?s health products; blood glucose monitoring and insulin delivery products; professional diagnostic products; and disposable contact lenses. The company was founded in 1886 and is based in Ne w Brunswick, New Jersey.

Advisors' Opinion:
  • [By The Part-time Investor]

    The following stocks met the criteria in January of 2008 and were put into the initial portfolio:

    Abbot Labs (ABT)Advanced data processing (ADP)Associated Banc-Corp (ASBC)Bank of America (BAC)BB&T Corp. (BBT)Bemis Company (BMS)Anheuser Busch (BUD)The Chubb Corporation (CB)Clorox (CLX)Comerica Inc. (CMA)Diebold Inc. (DBD)Emerson Electronics (EMR)First Dollar Corp. (FDO)First Third BanCorp. (FITB)Gannett Co, Inc. (GCI)General Electric (GE)Hershey (HSY)Illinois Tools Works (ITW)Johnson and Johnson (JNJ)Leggett and Platt (LEG)Eli Lilly (LLY)La-Z-Boy (LZB)McDonald's (MCD)Marsh and Ilsley (MI)M&T Bancorp (MTB)PepsiCo (PEP)Pfizer (PFE)Procter & Gamble (PG)Pentair Ltd. (PNR)Regions Financial Corp. (RF)Rohm and Haas (ROH)RPM International (RPM)Sherwin Williams (SHW)Sysco Corp. (SYY)UDR Inc. (UDR)

    Historical quotes were taken from Yahoo Finance. $10,000 was put into each position, to the nearest whole share, so a total of $349,262.89 was invested. From 1/15/08 through 5/16/13 all dividends were reinvested back into the stock that paid them. If a dividend cut was announced, that stock was sold on the ex-div date of the new, lower dividend.

  • [By Matt Thalman]

    Two other big Dow winners came from the health-care industry as Johnson & Johnson (NYSE: JNJ  ) rose 2.28% and Pfizer (NYSE: PFE  ) gained 2.11%. Johnson & Johnson reported earnings earlier in the week and the company beat on both the top and bottom lines, but after earnings were announced, shares closed even on Tuesday, compared to Monday's close, at $90.40. While investors surely liked the fact that estimates had been topped, they didn't seem to be thrilled with some comments by management that pricing pressure was increasing. But�a poor earnings report, an FDA warning, and weak guidance moving forward from Intuitive Surgical (NASDAQ: ISRG) yesterday�make Johnson & Johnson's medical device unit look stronger than ever. And that's why I believe shares of J&J moved higher today.

  • [By Reuters]

    Richard Drew/APA board overlooking the floor of the New York Stock Exchange shows an intraday number above 1,600 for the S&P 500 on Friday. A big gain in the job market lifted the stock market to a record high. NEW YORK -- The Dow and S&P 500 advanced to all-time closing highs on Friday, with major indexes jumping 1 percent after an unexpectedly strong April jobs report eased concerns about an economic slowdown. The S&P closed above 1,600 and the Dow briefly traded above 15,000 for the first time as stocks extended this year's rally. Bellwether companies, including Chevron Corp. (CVX), Boeing Co. (BA) and Johnson & Johnson (JNJ), reached 52-week highs. The Russell 2000 stock index of mid- and small cap companies also hit a record, confirming the broadness of the rally. About 70 percent of stocks on both the New York Stock Exchange and the Nasdaq ended in positive territory. Non-farm payrolls rose by 165,000 last month and the unemployment rate fell to 7.5 percent, a four-year low, from 7.6 percent, the government said. In addition, hiring was much stronger than previously thought in February and March. Investors welcomed the gains after weeks of disappointing data, including tepid manufacturing reports, that suggested the economic recovery was losing steam. "We were all wringing our hands over the past month but this alleviates fears about a sharp spring slowdown," said Brad Sorensen, director of market and sector analysis at Charles Schwab in Denver. The Dow Jones industrial average (^DJI) was up 140.61 points, or 0.95 percent, at 14,972.19. The Standard & Poor's 500 Index (^GSPC) was up 16.63 points, or 1.04 percent, at 1,614.22. The Nasdaq Composite Index (COMPX) was up 38.01 points, or 1.14 percent, at 3,378.63. Both the Dow and S&P ended at all-time closing highs. For the week, the Dow rose 1.8, the S&P gained 2 percent and the Nasdaq rose 3 percent in its biggest weekly climb since the first week of the year. Sectors ti

  • [By Jayson Derrick]

    This morning, Johnson & Johnson (NYSE: JNJ) reported its first quarter results. The company announced an EPS of $1.54, beating the consensus estimate of $1.48. Revenue of $18.11 billion beat the consensus estimate of $18.0 billion. Net earnings for the quarter rose to $4.73 billion from $3.49 billion in the same quarter last year as the company saw several successful new product launches and continued growth of its existing product portfolio. Johnson & Johnson issued guidance and sees its full year 2014 EPS to be in a range of $5.80 to $5.90, in-line with the consensus estimate. Shares gained 2.11 percent, closing at $99.19.

Top Medical Stocks To Buy Right Now: VolitionRX Ltd (VNRX)

VolitionRX Limited, formerly Standard Capital Corporation, incorporated on September 24, 1998, through its wholly owned subsidiary Singapore Volition Pte Limited (Volition), is a life sciences company focused on developing blood-based diagnostic tests. As of October 12, 2011, Volition was developing a range of blood-based epigenetic cancer screening tests, which will be released for research then clinical use in Europe, North America and globally. The tests will enable doctors to screen for the general presence of cancer in the body with a single blood test, and investigate, which cancer is present in many of those cancer positive patients using a panel of tests. On October 6, 2011, the Company announced the closure of the share exchange agreement with the Company. On October 6, 2011, Volition became a wholly owned subsidiary of the Company.

Volition�� HyperGenomics technology will determine specific epigenetic signatures from cancer biopsies. The HyperGenomics range of tests will be used as a second line once cancer has been diagnosed, to determine the specific subtype of disease and to help decide the most appropriate therapy. Volition is developing a non-invasive blood test for endometriosis, based on its Nucleosomics technology.

Advisors' Opinion:
  • [By Peter Graham]

    At the end of last week, small cap stocks Senesco Technologies, Inc (OTCBB: SNTI), VolitionRX Ltd (OTCMKTS: VNRX) and Micromem Technologies Inc (OTCBB: MMTIF) were all trending upwards ��ending up 13.65%, 8.73% and 7.61%, respectively, on Friday. However, it�� a new trading week with the last two trading days for the year. So what direction will these three small caps head in for the end of this year and into next year? Here is a quick look to help you decide on a trading or investment strategy:

Top Medical Stocks To Buy Right Now: Medizone International Inc (MZEI)

Medizone International, Inc. (Medizone), incorporated in January 31, 1986, is a development-stage company. The Company is engaged in research into the medical uses of ozone. Medizone focuses in the field of hospital sterilization. It is a research and development company engaged in developing its AsepticSure. The Company is developing an ozone-based technology (AsepticSure) for decontaminating and sterilizing hospital surgical suites, emergency rooms, and intensive care units.

The Company started hospital beta-testing of a prototype system utilizing the original technology. The first round of in-hospital beta-testing for this AsepticSure hospital disinfection system was completed at a Hotel Dieu hospital in Kingston, Ontario, Canada. In addition to the hospital disinfection system, it employs an ozone-destruct unit which is used following disinfection of the treated infrastructure to reverse the O3 gas in the space, and turn it back into O2 in a short period of time. The Company�� subsidiaries include Medizone Canada, Ltd. (MedCan). As of December 31, 2011, the Company had not generated any revenues.

Advisors' Opinion:
  • [By CRWE]

    Today, MZEI surged (+5.64%) up +0.0048 at $.0899 with 21,900 shares in play thus far (ref. google finance Delayed: 1:32PM EDT October 16, 2013).

    Medizone International, Inc. previously reported that its WHO award-winning green infection control technology, AsepticSure has been Granted a patent by the United States Patent and Trademark office. (US 61/223,219) titled “Healthcare Facility Disinfecting System”. The AsepticSure infection control system has repeatedly demonstrated 100% microbial kill rates when used to decontaminate hospital rooms of the causative agents of HAI (hospital acquired infections).

    “With patent protection now established in the United States, Canada and Singapore and pending applications in process for the 37 member countries of the EU as well as Korea, Japan, China, India, Brazil and Mexico, our patent momentum is clearly gaining strength,” stated Edwin Marshall, Medizone’s CEO.

Top Medical Stocks To Buy Right Now: Oramed Pharmaceuticals Inc (ORMP)

Oramed Pharmaceuticals Inc., incorporated on March 10, 2011, is a development-stage pharmaceutical company. The Company is engaged in the research and development of pharmaceutical solutions, including an orally ingestible insulin capsule or tablet to be used for the treatment of individuals with diabetes, use of orally ingestible capsules, tablets or pills for delivery of other polypeptides. The Company owns oral dosage form drug portfolio, it is, on an on-going basis, considering in-licensing and other means of obtaining additional technologies to complement and/or expand the product portfolio. The Company�� products include ORMD-0801 - Oral Insulin Capsule and ORMD-0901 - Oral Exenatide.

The Company focuses to conduct research and development on the technology covered by the patent application Methods and Composition for Oral Administration of Proteins. Through its research and development efforts, it focuses to develop an oral dosage form that will withstand the chemical environment of the stomach and intestines and will be effective in delivering active insulin for the treatment of diabetes. It intends to conduct the clinical trials to file an Investigational New Drug (IND), application with the United States Food and Drug Administration (FDA). It also focuses to conduct research and development by deploying its drug delivery technology for the delivery of other polypeptides in addition to insulin, and to develop other pharmaceutical products.

Advisors' Opinion:
  • [By Lisa Levin]

    Oramed Pharmaceuticals (NASDAQ: ORMP) shares moved up 21.26% to $14.20. The volume of Oramed Pharmaceuticals shares traded was 621% higher than normal. Oramed shares have jumped 187.01% over the past 52 weeks, while the S&P 500 index has gained 28.75% in the same period.

  • [By Lisa Levin]

    Oramed Pharmaceuticals (NASDAQ: ORMP) shares moved up 15.68% to $17.85. The volume of Oramed Pharmaceuticals shares traded was 971% higher than normal. Oramed received patent allowance in Israel, Australia for platform technology in oral delivery of proteins.

  • [By Ben Levisohn]

    Oramed Pharmaceuticals (ORMP) has dropped 19% to $12.11 after the company said it would sell nearly 1.6 million shares of stock for $10 a share.

    BP plc (BP) has fallen 0.7% to $47.24 after a U.S. judge refused its request to revise the way damages from the Deepwater Horizon oil spill are calculated.

Top Medical Stocks To Buy Right Now: Medical Care Technologies Inc (MDCE)

Medical Care Technologies Inc., formerly AM Oil Resources & Technology Inc., incorporated on February 27, 2007, is a development-stage company. The Company is engaged in the development and maintenance of secure medical information systems used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The Company operates in three business segments: Medical Management Software Systems, Medi-Clinics and Pharmaceutical and Nutraceutical Products.

Medical Management Software Systems

The Company produces a range of medical management software systems, which could be used in a range of healthcare settings to electronically connect the healthcare industry with the consumer. It includes healthcare monitoring devices for glucose monitoring and cardiovascular monitoring and solutions, among others. The primary customers served by the software systems are hospitals and clinics, physicians��office practices, consumers and retail pharmacies, pharmaceutical companies and healthcare providers.

The Company have developed the Med-Suite Professional Practice Management information system. The Med-Suite is geared for usage by healthcare providers, such as physicians and nurses in hospitals, nursing homes and clinics. The e-management solution addresses the needs of healthcare providers to manage and communicate administrative and clinical data.

The second information systems product developed by the Company is the Tele-Health Suite. Tele-Health functions similarly to a hospital or doctor�� chart and is an interactive record to communicate patient data between healthcare providers and, healthcare providers and patients for treatment support, management and monitoring of the patient�� health.

The CareBox concept is a product designed for persons needing Tele-Health but who do not have access to the necessary computer hardware. The CareBox is a personal Internet communication de! vice that functions as the interface to the subscriber based network. The Company�� network would provide users access to telecommunication, tele-medicine applications and product access. The CareBox is engaged in the development of healthcare service delivery to the individual subscriber.

The CareBox system offers remote, real-time, audio-visual communication between patient and healthcare personnel. It offers a complete medical assessment, diagnosis, and treatment from a remote location. The CareBox processes on-site collections of physiological measurements and provides bi-directional audio-video communication.

The CareBox Bluetooth software requirements installed to mobile computing devices. It is compatible with iPhone, BlackBerry and other mobile cellular phone protocols. It enables wireless upload of personal medical information from medical and wellness monitoring devices.

Using the online facility, healthcare providers (doctors, nurses) could admit and assess patients, and subsequently create and revise individual healthcare plans. Attachments could be made to the CareBox, for monitoring blood-oxygen levels, temperature, blood pressure, pulse, as well as blood glucose levels. If readings are outside normal limits, the system would initiate a pre-programmed response and instruction for client intervention would be given. The system provides continuous monitoring at home for the clients, which serves to lengthen the period of time a person could live independently, while reducing the number of re-admissions to care facilities.

Retail Pharmacies and Retail Medical Clinics

The Company focuses to open professional, and convenience retail pharmacies and also retail medical clinics. Within the pharmacies, it focuses to have over the counter (OTC) drugs, nutritional supplements, herbal products, personal care products, family care products, as well as products, including consumable, seasonal and promotional items. The customers woul! d also ha! ve access to the medical software and hardware systems. It plans to open retail medical clinics, with a specific view to treating patients with telemedicine as well as a traditional treatment format.

Pharmaceutical and Nutraceutical Products

The Company plans to develop or source and sell pharmaceutical and nutraceutical products, and a range of other merchandise, including over-the-counter medicines, herbal products, personal care products, family care products in the planned Medi-Clinics, through the Website, retail pharmacies and through established sales and distribution channels in the People�� Republic of China. It would also offer private label products. Med-Suite, in concert with a person�� secure personal health record, would allow the medical professional to communicate pharmaceutical, administrative, clinical data in a cost-effective manner. The Company plans to use Med-Suite to provide marketing tools for pharmaceutical sales automation.

Advisors' Opinion:
  • [By Peter Graham]

    What�� the Catch With Timios National Corp? According to various disclosures, at least one promoter expects to be compensated up to $140k to talk about Timios National Corp. However, Timios National Corp itself has been fairly quiet with news for the past several months except for financial filings. Probably the most recent relevant filing dates from September and is about an Asset Purchase Agreement with Adobe Title, LLC, whereby HOMS acquired all of the assets and properties of, and assumed certain liabilities, from the latter in consideration of $500,000 plus an earn-out equal to 7.25% of the Gross Revenue up to a maximum of $3,500,000 starting approximately six months from the date of the Agreement and ending on the forty-eighth monthly anniversary of such start date. A quick look at Timios National Corp�� financials reveals revenues of $6,810k (most recent reported quarter), $8,519k, $7,355k and $6,866k for the past four reported quarters along with a net loss of $120k (most recent reported quarter), net income of $329k and $66, and a net loss of $2,073k. At the end of September, Timios National Corp had $776k in cash to cover $3,661k in current liabilities and $6,700k in total liabilities. So its hard to explain the sudden share price decline last Friday.

    Medical Care Technologies Inc (OTCMKTS: MDCE) Says Its Well Positioned to Profit From Health Care in Hong Kong

    Small cap Medical Care Technologies Inc, through joint ventures or Chinese subsidiaries, develops a network of family and children's health facilities in the larger urban areas throughout China. Services are geared towards the advancing economic middle-class Chinese families. On Friday, Medical Care Technologies Inc sank 25% to $0.0012 for a market cap of $2,060 plus MDCE is up 1,100% over the past year and up 20% over the past five years according to Google Finance.

Top Medical Stocks To Buy Right Now: Mast Therapeutics Inc (MSTX)

Mast Therapeutics, Inc., formerly ADVENTRX Pharmaceuticals, Inc., incorporated in December 1995, is a development-stage company biopharmaceutical company focused on developing product candidates. The Company's product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves microvascular blood flow and has application in treating a range of diseases and conditions, such as complications arising from sickle cell disease. As of December 31, 2011, the Company also is developing ANX-514, a detergent-free formulation of the chemotherapy drug docetaxel. The Company offers ANX-188 (purified poloxamer 188), ANX-514 (docetaxel for injectable emulsion) and Exelbine (vinorelbine injectable emulsion). In April 2011, the Company acquired SynthRx, Inc. In February 2014, Mast Therapeutics Inc completed its acquisition of Aires Pharmaceuticals, Inc. Aires became a wholly-owned subsidiary of Mast Therapeutics.

ANX-188 (purified poloxamer 188)

ANX-188 is an aqueous solution of a purified form of poloxamer 188. Poloxamer 188 (P1880, is a nonionic, block copolymer that has been found to improve microvascular blood flow by reducing viscosity, particularly under low shear conditions, and by reducing adhesive frictional forces. The Company�� purified form of P188 (purified P188), which is the active ingredient in ANX-188, was designed to eliminate certain low molecular weight substances present in P188 (non-purified), which is primarily responsible for the moderate to moderately severe elevations in serum creatinine levels (acute renal dysfunction) observed in prior clinical studies of P188 (non-purified). Purified P188 has been evaluated in multiple clinical studies by a prior sponsor, including a 255-patient, phase III study.

ANX-514 (docetaxel for injectable emulsion)

ANX-514 is a detergent-free emulsion formulation of docetaxel, an intravenously-injected chemotherapy drug commonly used to treat solid tumors. Taxotere, a branded form! ulation of docetaxel, is approved to treat breast, non-small cell lung, prostate, gastric, and head and neck cancers. ANX-514 was designed to have clinically comparable release of docetaxel relative to Taxotere while eliminating the presence of polysorbate 80 and ethanol, both of which are used to solubilize docetaxel in the Taxotere formulation. The ANX-514 formulation solubilizes docetaxel using oil droplets consists of a combination of non-toxic excipients. Docetaxel is contained within these oil droplets and can be administered intravenously without using detergents as pharmaceutical vehicles. Once in central circulation, the emulsion is metabolized rapidly, leaving chemically-identical active ingredient to exert its cytotoxic effect. ANX-514 may reduce the incidence and severity of hypersensitivity reactions and delay the onset of fluid retention.

Exelbine (vinorelbine injectable emulsion)

Exelbine is an emulsion formulation of the chemotherapy drug vinorelbine. Navelbine, a branded formulation of vinorelbine, is approved in the United States to treat advanced non-small cell lung cancer as a single agent or in combination with cisplatin, and approved in the European Union to treat non-small cell lung cancer and advanced or metastatic breast cancer.

In August 2011, the Company received a complete response letter from the Food and Drug Administration (FDA) stating that it could not approve the Exelbine Non Disclosure Agreement (NDA) in its present form and that the bioequivalence study would need to be repeated because the authenticity of the drug products used in the bioequivalence trial could not be verified in accordance with FDA standards. However, the Company elected to discontinue independent development of Exelbine and as of December 31, 2011, the Company was seeking a partner or outside investor for the program to complete the necessary bioequivalence study.

The Company competes with GlaxoSmithKline, Provenge and Pfizer.

Advisors' Opinion:
  • [By Lauren Pollock]

    Mast Therapeutics Inc.(MSTX) said the U.S. Food and Drug Administration gave orphan-drug designation to its MST-188 drug for the treatment of acute limb ischemia, providing a boost for the biopharmaceutical firm. Shares surged.

  • [By John Udovich]

    The start of 2014 shows that biotech is still a hot area with the sector along with small cap biotech stocks like AMAG Pharmaceuticals, Inc (NASDAQ: AMAG), Mast Therapeutics Inc (NYSEMKT: MSTX), Cell Therapeutics Inc (NASDAQ: CTIC), Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) and TNI BioTech (OTCMKTS: TNIB) producing news or returns�plus Auspex Pharmaceuticals (NASDAQ: ASPX), Cara Therapeutics (NASDAQ: CARA), Egalet (NASDAQ: EGLT), Flexion Therapeutics (NASDAQ: FLXN) and Ultragenyx Pharmaceutical (NASDAQ: RARE) are among the (many�� planned biotech IPOs that have recently been announced publicly:

Top Medical Stocks To Buy Right Now: DiaMedica Inc (DMA)

DiaMedica Inc. (DiaMedica) is a development-stage company. The Company is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of diabetes and related diseases. DiaMedica's compound, DM-199, is a recombinant human protein for the treatment of both Type I and Type II diabetes and their complications. DiaMedica is starting a Phase I/II clinical trial for DM-199. DM-199 is a recombinant human protein, which improves glucose control, protects beta cells through the expansion of a population of antigen-specific immunosuppressive cells (Tregs), and proliferates insulin producing beta cells through the activation of certain growth factors. The Company�� DM-204 is a G-protein-coupled receptor agonist (GPCR) monoclonal antibody to treat Type II diabetes and some of the associated complication's. activating a receptor resulted in insulin sensitivity, insulin secretion and vasodilation. Advisors' Opinion:
  • [By Richard Rhodes]

    Given this economic backdrop, and developing pressure on corporate revenues, margins, and earnings, we feel that risk is being misplaced at current levels.

    The 14-day and 40-day models are now overbought. Now, the 14-day and 40-day are peaking, which would certainly indicate a correction stands as the highest probability.

    The % of stocks above their 10-day moving average (dma) is at the 70%-level; still a major divergence with prices.

    The % of stocks above their 200-dma stands at 77%. The 87% level marked previous highs. The 50-dma/150-dma cross breakdown now confirms a larger correction. Bottoms form between 30%-40%.

    Overall, the risk-reward remains skewed to the downside, regardless of whether prices remain above trendline resistance, as our model group suggests a correction to the 110-day moving average, currently at S&P 1711.

    A clear breakdown at that level would accelerate the decline towards the wide 200-dma and 380-dma range, between 1657-1571.